<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Drugs for the acute treatment of migraine in children and adolescents - Richer, L - 2016 | Cochrane Library</title> <meta content="Drugs for the acute treatment of migraine in children and adolescents - Richer, L - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005220.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Drugs for the acute treatment of migraine in children and adolescents - Richer, L - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005220.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005220.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Drugs for the acute treatment of migraine in children and adolescents" name="citation_title"/> <meta content="Lawrence Richer" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="lricher@ualberta.ca" name="citation_author_email"/> <meta content="Lori Billinghurst" name="citation_author"/> <meta content="The Children's Hospital of Philadelphia" name="citation_author_institution"/> <meta content="Meghan A Linsdell" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="Kelly Russell" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="Ben Vandermeer" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="Ellen T Crumley" name="citation_author"/> <meta content="Health Info and Searching Practice Inc" name="citation_author_institution"/> <meta content="Tamara Durec" name="citation_author"/> <meta content="Evidence-based Practice Centre" name="citation_author_institution"/> <meta content="Terry P Klassen" name="citation_author"/> <meta content="Manitoba Institute of Child Health" name="citation_author_institution"/> <meta content="Lisa Hartling" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD005220.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005220.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005220.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005220.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetaminophen [therapeutic use]; Analgesics, Non-Narcotic [*therapeutic use]; Dihydroergotamine [therapeutic use]; Ibuprofen [therapeutic use]; Migraine Disorders [*drug therapy]; Serotonin Receptor Agonists [adverse effects, *therapeutic use]; Time Factors; Tryptamines [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005220.pub2&amp;doi=10.1002/14651858.CD005220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005220\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005220\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005220.pub2",title:"Drugs for the acute treatment of migraine in children and adolescents",firstPublishedDate:"Apr 19, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005220.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005220.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005220.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005220.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005220.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005220.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005220.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005220.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005220.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005220.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8975 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005220.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-sec-0068"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-sec-0010"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-sec-0011"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-sec-0036"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-sec-0058"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/appendices#CD005220-sec-0076"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/supinfo/CD005220StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/supinfo/CD005220StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Drugs for the acute treatment of migraine in children and adolescents</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Lawrence Richer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0005">Lori Billinghurst</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0006">Meghan A Linsdell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0007">Kelly Russell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0008">Ben Vandermeer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0009">Ellen T Crumley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0010">Tamara Durec</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0011">Terry P Klassen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information#CD005220-cr-0012">Lisa Hartling</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information/en#CD005220-sec-0081">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005220.pub2">https://doi.org/10.1002/14651858.CD005220.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005220-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005220-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005220-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005220-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005220-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005220-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005220-abs-0001" lang="en"> <section id="CD005220-sec-0001"> <h3 class="title" id="CD005220-sec-0001">Background</h3> <p>Numerous medications are available for the acute treatment of migraine in adults, and some have now been approved for use in children and adolescents in the ambulatory setting. A systematic review of acute treatment of migraine medication trials in children and adolescents will help clinicians make evidence‐informed management choices. </p> </section> <section id="CD005220-sec-0002"> <h3 class="title" id="CD005220-sec-0002">Objectives</h3> <p>To assess the effects of pharmacological interventions by any route of administration versus placebo for migraine in children and adolescents 17 years of age or less. For the purposes of this review, children were defined as under 12 years of age and adolescents 12 to 17 years of age. </p> </section> <section id="CD005220-sec-0003"> <h3 class="title" id="CD005220-sec-0003">Search methods</h3> <p>We searched seven bibliographic databases and four clinical trial registers as well as gray literature for studies through February 2016. </p> </section> <section id="CD005220-sec-0004"> <h3 class="title" id="CD005220-sec-0004">Selection criteria</h3> <p>We included prospective randomized controlled clinical trials of children and adolescents with migraine, comparing acute symptom relieving migraine medications with placebo in the ambulatory setting. </p> </section> <section id="CD005220-sec-0005"> <h3 class="title" id="CD005220-sec-0005">Data collection and analysis</h3> <p>Two reviewers screened titles and abstracts and reviewed the full text of potentially eligible studies. Two independent reviewers extracted data for studies meeting inclusion criteria. We calculated the risk ratios (RRs) and number needed to treat for an additional beneficial outcome (NNTB) for dichotomous data. We calculated the risk difference (RD) and number needed to treat for an additional harmful outcome (NNTH) for proportions of adverse events. The percentage of pain‐free patients at two hours was the primary efficacy outcome measure. We used adverse events to evaluate safety and tolerability. Secondary outcome measures included headache relief, use of rescue medication, headache recurrence, presence of nausea, and presence of vomiting. We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation) and created 'Summary of findings' tables. </p> </section> <section id="CD005220-sec-0006"> <h3 class="title" id="CD005220-sec-0006">Main results</h3> <p>We identified a total of 27 randomized controlled trials (RCTs) of migraine symptom‐relieving medications, in which 9158 children and adolescents were enrolled and 7630 (range of mean age between 8.2 and 14.7 years) received medication. Twenty‐four studies focused on drugs in the triptan class, including almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan + naproxen sodium, and zolmitriptan. Other medications studied included paracetamol (acetaminophen), ibuprofen, and dihydroergotamine (DHE). More than half of the studies evaluated sumatriptan. All but one study reported adverse event data. Most studies presented a low or unclear risk of bias, and the overall quality of evidence, according to GRADE criteria, was low to moderate, downgraded mostly due to imprecision and inconsistency. Ibuprofen was more effective than placebo for producing pain freedom at two hours in two small studies that included 162 children (RR 1.87, 95% confidence interval (CI) 1.15 to 3.04) with low quality evidence (due to imprecision). Paracetamol was not superior to placebo in one small study of 80 children. Triptans as a class of medication were superior to placebo in producing pain freedom in 3 studies involving 273 children (RR 1.67, 95% CI 1.06 to 2.62, NNTB 13) (moderate quality evidence) and 21 studies involving 7026 adolescents (RR 1.32, 95% CI 1.19 to 1.47, NNTB 6) (moderate quality evidence). There was no significant difference in the effect sizes between studies involving children versus adolescents. Triptans were associated with an increased risk of minor (non‐serious) adverse events in adolescents (RD 0.13, 95% CI 0.08 to 0.18, NNTH 8), but studies did not report any serious adverse events. The risk of minor adverse events was not significant in children (RD 0.06, 95% CI − 0.04 to 0.17, NNTH 17). Sumatriptan plus naproxen sodium was superior to placebo in one study involving 490 adolescents (RR 3.25, 95% CI 1.78 to 5.94, NNTB 6) (moderate quality evidence). Oral dihydroergotamine was not superior to placebo in one small study involving 13 children. </p> </section> <section id="CD005220-sec-0007"> <h3 class="title" id="CD005220-sec-0007">Authors' conclusions</h3> <p>Low quality evidence from two small trials shows that ibuprofen appears to improve pain freedom for the acute treatment of children with migraine. We have only limited information on adverse events associated with ibuprofen in the trials included in this review. Triptans as a class are also effective at providing pain freedom in children and adolescents but are associated with higher rates of minor adverse events. Sumatriptan plus naproxen sodium is also effective in treating adolescents with migraine. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005220-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005220-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005220-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005220-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005220-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005220-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005220-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005220-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD005220-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005220-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005220-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005220-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005220-abs-0002" lang="en"> <h3>Drugs for the acute treatment of migraine in children and adolescents</h3> <p><b>Background and review question</b> </p> <p>Migraine is a painful and debilitating disorder that is common in children (under 12 years of age) and adolescents (12 to 17 years of age). Common symptoms reported during a migraine attack are headache, nausea, vomiting, and sensitivity to light and sound. Many treatments for migraine are available, of which the most common are paracetamol (also known as acetaminophen), ibuprofen and other anti‐inflammatories, and triptans. Not all triptan medications are approved for use in children or adolescents, and approvals vary from country to country. </p> <p><b>Study characteristics</b> </p> <p>In our review, we looked at 27 randomized controlled trials of drugs compared to placebo to find out which treatments were effective at providing pain freedom two hours after treatment. We also wanted to know what side effects might be caused by the treatments. A total of 7630 children received medication in the studies. The evidence is current to February 2016. Each study had between 13 and 888 participants. Their average age was 12.9 years and ranged from 8.2 to 14.7 years. Nineteen of the studies were funded by the drug manufacturer. </p> <p><b>Key results</b> </p> <p>Ibuprofen appears to be effective in treating children with migraine, but the evidence is limited to only two small trials. Ibuprofen is readily available and inexpensive, making it an excellent first choice for migraine treatment. Paracetamol was not shown to be effective in providing pain freedom in children, but we only found one small study. Triptans are a type of medication designed specifically to treat migraine and are often effective at providing greater pain freedom in children and adolescents. The triptans examined in children included rizatriptan and sumatriptan, while almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan were examined in adolescents. The combination of sumatriptan plus naproxen sodium is also effective at treating adolescents with migraine. Overall, there is a risk that the triptan medications may cause minor unwanted side effects like taste disturbance, nasal symptoms, dizziness, fatigue, low energy, nausea, or vomiting. The studies did not report any serious side effects. </p> <p><b>Quality of the evidence</b> </p> <p>The overall quality of the evidence provided by the review was moderate for the triptans, but low for paracetamol and ibuprofen, as we only identified a few studies. More studies need to look at the effects of each of the migraine treatments in children and adolescents separately. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005220-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005220-sec-0068"></div> <h3 class="title" id="CD005220-sec-0069">Implications for practice</h3> <section id="CD005220-sec-0069"> <p>We found low quality evidence from two small studies that ibuprofen appears to improve pain relief in children with migraine. We have only limited information on adverse events in the trials included in this review. There is insufficient evidence in favor of paracetamol. We did not identify evidence regarding early treatment, the use of other NSAIDs, or the combination of these analgesics with other medications (e.g. metoclopramide, caffeine) in children or adolescents. </p> <p>For children and adolescents with migraine, triptans appear to be effective in the acute treatment of migraine. Sumatriptan plus naproxen sodium is effective in adolescents, but we did not find any studies in children. Triptans are generally safe but carry an increased risk of minor (non‐serious) adverse events. </p> <p>For clinicians, the choice of triptan medication may be guided by factors such as patient preference, route of delivery, or palatability. A parent who responds well to one of the medications may be more likely to request that medication for their child. More than half of the triptan studies in children and adolescents were of sumatriptan, and this medication serves as the reference drug in this class. The choice of triptan may also be based on local availability, drug cost reimbursement, and regulatory approval. We found inconsistent evidence in our subgroup analysis of the intranasal versus oral triptan preparations, but patients may prefer one route over the other (e.g. intranasal if significant vomiting or oral if patient has chronic rhinitis). </p> <p>For policymakers and funders, the triptan class of medications, as well as sumatriptan in combination with naproxen sodium, are suitable options for children and adolescents with migraine. One or more of these medications should be made available in situations where ibuprofen has failed to provide pain freedom or headache relief. </p> </section> <h3 class="title" id="CD005220-sec-0070">Implications for research</h3> <section id="CD005220-sec-0070"> <section id="CD005220-sec-0071"> <h5 class="title">General</h5> <p>Future studies should separate the childhood and adolescent age groups to enable separate meta‐analyses of these groups. More studies of simple analgesics commonly used in the treatment of migraine like paracetamol and ibuprofen, other NSAIDs, or head to head comparisons are warranted. </p> </section> <section id="CD005220-sec-0072"> <h5 class="title">Design</h5> <p>Studies employing a cross‐over design were associated with significantly higher effect size estimates. Similar findings have been reported previously (<a href="./references#CD005220-bbs2-0052" title="LathyrisDN , TrikalinosTA , IoannidisJP . Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. International Journal of Epidemiology2007;36(2):422-30. [DOI: 10.1093/ije/dym001]">Lathyris 2007</a>). This may have been due to inadequate blinding in cross‐over studies or higher effect estimates due to the smaller sample size. Guidelines for controlled trials of drugs in migraine advocate the use of either cross‐over or parallel design (<a href="./references#CD005220-bbs2-0066" title="Tfelt-HansenP , PascualJ , RamadanN , DahlofC , D'AmicoD , Diener H-C, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia2012;32(1):6-38. [DOI: 10.1177/0333102411417901]">Tfelt‐Hansen 2012</a>). </p> </section> <section id="CD005220-sec-0073"> <h5 class="title">Measurement (endpoints)</h5> <p>Pain freedom as an outcome measure demonstrated low heterogeneity between studies and may be most suitable as a primary outcome measure. Data on other outcome measures (e.g. nausea, headache relief, etc.) should also be collected, as described in the guidelines for controlled trials of drugs in migraine (<a href="./references#CD005220-bbs2-0066" title="Tfelt-HansenP , PascualJ , RamadanN , DahlofC , D'AmicoD , Diener H-C, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia2012;32(1):6-38. [DOI: 10.1177/0333102411417901]">Tfelt‐Hansen 2012</a>). </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005220-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005220-sec-0008"></div> <div class="table" id="CD005220-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Should ibuprofen be used to treat children with migraine?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Ibuprofen compared with placebo in children with migraine</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : acute treatment of migraine in children<br/><b>Setting</b> : ambulatory<br/><b>Intervention</b> : ibuprofen<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with Ibuprofen</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain freedom at 2 h</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.87<br/>(1.15 to 3.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⨁⨁◯◯<sup>b,c</sup><br/>Low </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>499 per 1000<br/>(307 to 811) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> <p>(− 13 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RD 0.00</p> <p>(− 0.13 to 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality</b> : We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality</b>: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>RD</b>: risk difference </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The response in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>b</sup>In the two studies, there were no serious risks of bias, inconsistency, indirectness, or publication bias. We downgraded quality of evidence by two levels due to very serious imprecision (small sample size, few events, and wide confidence interval). </p> <p><sup>c</sup>High (⨁⨁⨁⨁) = further research is very unlikely to change our confidence in the estimate of effect; Moderate (⨁⨁⨁◯) = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low (⨁⨁◯◯) = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very Low (⨁◯◯◯) = any estimate of effect is very uncertain. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005220-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Should triptans be used to treat children with migraine?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Triptans compared with placebo in children with migraine</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : acute treatment of migraine in children<br/><b>Setting</b> : ambulatory<br/><b>Intervention</b> : triptans<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with triptans</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain freedom at 2 h</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.67<br/>(1.06 to 2.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>345<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⨁⨁⨁◯<sup>b,c</sup><br/>MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Includes rizatriptan oral (1 study) and sumatriptan by nasal spray (2 studies)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>461 per 1000<br/>(292 to 723) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>176 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000</p> <p>(− 7 to 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RD 0.06</p> <p>(− 0.04 to 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>420</p> <p>(3 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality</b> : We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality</b>: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>RD</b>: risk difference. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The response in the intervention group (and its 95% confidence interval) is based on the assumed response in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>b</sup>In the three studies, there were no serious risks of bias, inconsistency, indirectness, or publication bias detected. Quality of evidence was downgraded by one level due to serious imprecision (small sample size, few events, and wide confidence interval). </p> <p><sup>c</sup>High (⨁⨁⨁⨁) = further research is very unlikely to change our confidence in the estimate of effect; Moderate (⨁⨁⨁◯) = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low (⨁⨁◯◯) = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very Low (⨁◯◯◯) = any estimate of effect is very uncertain. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005220-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Should triptans be used to treat adolescents with migraine?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Triptans compared with placebo in adolescents with migraine</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : acute treatment of migraine in adolescents<br/><b>Setting</b> : ambulatory<br/><b>Intervention</b> : Triptans<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with Triptans</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain freedom at 2 h</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(1.19 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6761<br/>(21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⨁⨁⨁◯<sup>b,c</sup><br/>MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Includes almotriptan (1 study), eletriptan (1 study), naratriptan (1 study), rizatriptan (4 studies), sumatriptan (10 studies), and zolmitriptan (4 studies) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>303 per 1000<br/>(273 to 338) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>184 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>24 per 1000</p> <p>(15 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RD 0.13</p> <p>(0.08 to 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7876</p> <p>(21 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality</b> : We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality</b>: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>RD</b>: risk difference. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The response in the intervention group (and its 95% confidence interval) is based on the assumed response in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>b</sup>Serious inconsistency was observed in the effect estimates. All of the triptans with only 1 study were not statistically superior to placebo (i.e. almotriptan, eletriptan, naratriptan) in producing pain freedom while the three triptans with 2 or more studies (i.e. rizatriptan, sumatriptan, and zolmitriptan) were statistically significant with a higher magnitude of effect. In the subgroup analysis of the individual triptan groups through, the subgroup differences were not statistically significant (P = 0.45). </p> <p><sup>c</sup>High (⨁⨁⨁⨁) = further research is very unlikely to change our confidence in the estimate of effect; Moderate (⨁⨁⨁◯) = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low (⨁⨁◯◯) = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very Low (⨁◯◯◯) = any estimate of effect is very uncertain. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005220-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Should sumatriptan plus naproxen sodium be used to treat adolescents with migraine?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Sumatriptan + naproxen sodium compared with placebo in adolescents with migraine</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : acute treatment of migraine in adolescents<br/><b>Setting</b> : ambulatory<br/><b>Intervention</b> : sumatriptan + naproxen sodium<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with Sumatriptan + naproxen sodium</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain freedom at 2 h</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.66<br/>(1.57 to 4.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>485<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⨁⨁⨁◯<sup>b,c</sup><br/>MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Doses including sumatriptan + naproxen 10 mg + 60 mg, 30 mg + 180 mg, and 85 mg + 500 mg were all well tolerated and demonstrated similar efficacy </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<br/>(163 to 394) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 per 1000</p> <p>(− 2 to 7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RD 0.03</p> <p>(− 0.02 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>490</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality</b> : We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality</b>: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>RD</b>: risk difference. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The response in the intervention group (and its 95% confidence interval) is based on the assumed response in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>b</sup>The confidence interval of the effect size is wide. The true effect may be substantially different than the estimated effect in producing pain freedom. </p> <p><sup>c</sup>High (⨁⨁⨁⨁) = further research is very unlikely to change our confidence in the estimate of effect; Moderate (⨁⨁⨁◯) = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low (⨁⨁◯◯) = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very Low (⨁◯◯◯) = any estimate of effect is very uncertain. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005220-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005220-sec-0009"></div> <p>Migraine is a common and disabling disease, affecting 3% to 10% of children and adolescents (<a href="./references#CD005220-bbs2-0063" title="StovnerLJ , HagenK , JensenR , KatsaravaZ , LiptonRB , ScherAI , et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia2007;27(3):193-210. [DOI: 10.1111/j.1468-2982.2007.01288.x]">Stovner 2007</a>). Children as young as two years of age may be affected, and most adults with migraine have their first headache in early childhood or adolescence (<a href="./references#CD005220-bbs2-0037" title="BilleB . A 40-year follow-up of school children with migraine. Cephalalgia1997;17(4):488-91; discussion 487. [DOI: 10.1046/j.1468-2982.1997.1704488.x]">Bille 1997</a>). Quality‐of‐life studies indicate that migraine has a significant negative impact on a child (<a href="./references#CD005220-bbs2-0058" title="PowersSW , PattonSR , HommelKA , HersheyAD . Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics2003;112(1 Pt 1):e1-5. [PMID: 12837897]">Powers 2003</a>; <a href="./references#CD005220-bbs2-0059" title="PowersSW , PattonSR , HommelKA , HersheyAD . Quality of life in paediatric migraine: characterization of age-related effects using PedsQL 4.0. Cephalalgia2004;24(2):120-7. [DOI: 10.1111/j.1468-2982.2004.00652.x]">Powers 2004</a>). Indeed, migraines can be a tremendous source of anxiety for children, adolescents, and their parents, disrupting both school obligations and parental work responsibilities. These concerns may be amplified when there is uncertainty on the physician's part as to the best treatment. </p> <p>The International Classification of Headache Disorders, 3<sup>rd</sup> edition, beta version (<a href="./references#CD005220-bbs2-0050" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629-808. [DOI: 10.1177/0333102413485658]">ICHD‐3 beta</a>), provides the most accepted and current definition of migraine. The presence of headache, often associated with nausea, vomiting, or both is common to adults, adolescents, and children with migraine. However, the criteria acknowledge that children and adolescents' migraines may be shorter but will last at least two hours, and the pain may be bilateral over the frontotemporal head regions or non‐pulsatile. Adolescents, like adults, will usually begin to report unilateral pulsatile pain. The presence of photophobia and phonophobia may need to be inferred from behaviour such as a preference for a quiet and dimly lit room during a migraine attack. </p> <p>Treatments for migraine include symptom‐relieving and preventive strategies. Preventive medications are used to reduce the frequency and severity of migraine attacks. Symptom‐relieving therapies commonly aim to eliminate head pain and reduce the symptoms associated with migraine, including nausea, phonophobia, and photophobia. Oral analgesics such as paracetamol and ibuprofen are the mainstay of acute therapy for migraine in children and adolescents (<a href="./references#CD005220-bbs2-0010" title="HämäläinenM , JonesM , LoftusJ , SaiersJ . Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. International Journal of Clinical Practice2002;56(9):704-9. [PMID: 12469987]SUM30009. A single centre, placebo-controlled, double blind, randomised cross-over, single attack study evaluating the efficacy and tolerability of sumatriptan nasal spray 10 mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura. http://www.gsk-clinicalstudyregister.com/study/SUM30009#rs (accessed 24 June 2015). ">Hämäläinen 2002</a>). However, other agents such as ergot derivatives (e.g. dihydroergotamine) and the serotonin 1b/1d receptor agonists (triptans) have demonstrated efficacy in adults. Many of these medications have now been studied in children and adolescents, and some are approved for use in the pediatric age group. A practice parameter on this topic has been published by the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society (<a href="./references#CD005220-bbs2-0054" title="LewisD , AshwalS , HersheyA , HirtzD , YonkerM , SilbersteinS . Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology2004;63(12):2215-24. [DOI: 10.1212/01.WNL.0000147332.41993.90]">Lewis 2004</a>). This systematic review will summarize and update the evidence base and provide a meta‐analysis of the data. </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005220-sec-0010" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005220-sec-0010"></div> <p>To assess the effects of pharmacological interventions by any route of administration versus placebo for migraine in children and adolescents 17 years of age or less. For the purposes of this review, children were defined as under 12 years of age and adolescents 12 to 17 years of age. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005220-sec-0011" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005220-sec-0011"></div> <section id="CD005220-sec-0012"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005220-sec-0013"> <h4 class="title">Types of studies</h4> <p>We included all prospective, placebo‐controlled trials of pharmacological interventions for symptomatic or acute treatment of migraine in children and adolescents in the outpatient setting if allocation to treatment groups was randomized (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). We included studies regardless of design (i.e. parallel‐group or cross‐over), publication status, or language of publication. We included cross‐over studies, as migraine is an episodic disorder, and we did not expect any carry‐over or period effects (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). We excluded non‐placebo‐controlled studies, concurrent cohort comparisons and other quasi‐ or non‐experimental designs. </p> </section> <section id="CD005220-sec-0014"> <h4 class="title">Types of participants</h4> <p>We included studies involving pediatric participants 17 years of age or less with a diagnosis of migraine with or without aura. For the purposes of the review, we defined children as under 12 years of age and adolescents as 12 to 17 years of age (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). We recorded inclusion age criteria, including median and mean age of subjects. We excluded studies involving both pediatric and adult patients unless they reported results separately for the pediatric patients. We analyzed separately the data from studies that included both children and adolescents when possible. If studies did not report the data separately, we used the mean age as a surrogate. If the mean age in the study was less than 12 years, we considered the study population to be of predominantly childhood age. If the mean age was greater than or equal to 12 years, we considered the study population to be of predominantly adolescent age. </p> <p>Migraine is defined by clinical symptoms and signs in the 3<sup>rd</sup> edition of the International Classification of Headache Disorders, beta version (<a href="./references#CD005220-bbs2-0050" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629-808. [DOI: 10.1177/0333102413485658]">ICHD‐3 beta</a>). <a href="./references#CD005220-bbs2-0050" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629-808. [DOI: 10.1177/0333102413485658]">ICHD‐3 beta</a> includes revised comments for the diagnosis of migraine in children and adolescents, including shorter duration of headache (2 to 72 hours), bilateral frontotemporal location, and the presence of photophobia and phonophobia as inferred from behaviour. There have been two other versions of the International Classification of Headache Disorder and a proposed revision of the 1988 criteria in the context of children or adolescents (<a href="./references#CD005220-bbs2-0051" title="International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia1988;8(Suppl 7):1-96.">IHS 1988</a>; <a href="./references#CD005220-bbs2-0049" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia2004;24(1 Suppl):1-160. [DOI: 10.1111/j.1468-2982.2003.00823.x]">ICHD‐2</a>; <a href="./references#CD005220-bbs2-0069" title="WinnerP , MartinezW , MateL , BelloL . Classification of pediatric migraine: proposed revisions to the IHS criteria. Headache1995;35(7):407-10.">Winner 1995</a>). We included a study in this review if investigators used any version of the International Headache Society classification systems above or the proposed revision for pediatrics for the diagnosis of migraine with or without aura. </p> </section> <section id="CD005220-sec-0015"> <h4 class="title">Types of interventions</h4> <p>We included studies allocating participants to receive a pharmacological intervention by any route of administration for symptomatic acute treatment of a migraine attack. Acceptable comparator groups included placebo or other active drug treatments. We identified the use of preventive medication and examined this in subgroup analysis, but discontinuation was not required for inclusion. </p> </section> <section id="CD005220-sec-0016"> <h4 class="title">Types of outcome measures</h4> <p>We chose outcomes to assess both efficacy and safety. We selected the primary efficacy outcome based on the suggested guidelines for controlled trials of drugs in migraine (<a href="./references#CD005220-bbs2-0066" title="Tfelt-HansenP , PascualJ , RamadanN , DahlofC , D'AmicoD , Diener H-C, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia2012;32(1):6-38. [DOI: 10.1177/0333102411417901]">Tfelt‐Hansen 2012</a>). The primary outcome for safety was based on the report of adverse events. All outcome measures were reported for the treatment of a single attack (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). </p> <section id="CD005220-sec-0017"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome measure for efficacy was the percentage of pain‐free participants at two hours; we defined pain freedom as the absence of pain at two hours before the use of additional or rescue medication (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). Headache relief is a frequently used primary outcome measure that is variably defined based on the scale used to assess pain. For example, if using the four level scale of none, mild, moderate, or severe pain, investigators or physicians may define headache relief as a decrease in pain from moderate or severe to mild or none. Some in the migraine research community have challenged the use of headache relief as a primary outcome measure; for example, migraine sufferers generally do not consider headache relief a success and expect pain freedom from an intervention (<a href="./references#CD005220-bbs2-0041" title="DaviesGM , SantanelloN , LiptonR . Determinants of patient satisfaction with migraine therapy. Cephalalgia2000;20(6):554-60. [DOI: 10.1046/j.1468-2982.2000.00082.x]">Davies 2000</a>; <a href="./references#CD005220-bbs2-0055" title="LiptonRB , HamelskySW , DaynoJM . What do patients with migraine want from acute migraine treatment?Headache2002;42(Suppl 1):3-9. [PMID: 11966858]">Lipton 2002</a>). Given these considerations, we classified headache relief as a secondary outcome measure (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). </p> <p>We used the percentage of participants with any adverse event(s) as the primary safety outcome measure, and this was required for inclusion in the analysis (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). We defined adverse events as any unwanted effect that occurred during treatment. We also documented the proportion of participants reporting any serious adverse events when possible. Serious adverse events included death, any life‐threatening condition, hospitalization, disability or permanent damage, required intervention to prevent permanent damage, or any other important medical event that could jeopardize the participant or require medical or surgical intervention. </p> <p>Some aspects of the original protocol were not necessary to implement given the way studies reported outcome data. We document these considerations in the <a href="#CD005220-sec-0085">Differences between protocol and review</a> section. </p> </section> <section id="CD005220-sec-0018"> <h5 class="title">Secondary outcomes</h5> <p>We assessed the following secondary outcome measures.</p> <p> <ul id="CD005220-list-0001"> <li> <p>Headache relief (headache response): the percentage of participants with headache relief at two hours is typically defined as a decrease in headache intensity from severe or moderate to mild or none at two hours prior to the use of rescue medication. When studies used alternate definitions of pain intensity (e.g. numerical scale), they needed to describe a level of relief that would be meaningful to a participant and to reflect a decrease in headache intensity similar to that assumed in the above definition. </p> </li> <li> <p>Rescue medication: the percentage of participants taking rescue medication at two hours or earlier to a maximum of six hours after the test drug. The definition of rescue medication was variable and often included any use of medication to treat the recurrence of headache within a specified timeframe (i.e. usually 24 hours). For the purposes of the review, rescue medication was defined as the use of any medication between 2 and 24 hours. </p> </li> <li> <p>Headache recurrence: the percentage of participants who were initially pain‐free or achieved the study primary outcome of headache relief within 2 hours without the use of rescue medication but who experienced recurrence of any headache from 2 to 48 hours. </p> </li> <li> <p>Presence of nausea: percentage of participants with nausea at two hours after taking the test drug. </p> </li> <li> <p>Presence of vomiting: percentage of participants with vomiting within two hours of taking the test drug. </p> </li> </ul> </p> <p>We did not include participant preference, presence of photophobia, or presence of phonophobia in the analysis as originally planned in the protocol (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). </p> </section> </section> </section> <section id="CD005220-sec-0019"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted a search of electronic databases in collaboration with a research librarian using search strategies to identify the highest level of evidence for the topic. In addition, we manually searched other sources listed below. </p> <section id="CD005220-sec-0020"> <h4 class="title">Electronic searches</h4> <p>We systematically searched the following databases:</p> <p> <ul id="CD005220-list-0002"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (1991 to 2013, Issue 3).</p> </li> <li> <p>OvidSP MEDLINE (1946 to February 2016).</p> </li> <li> <p>Ovid MEDLINE In‐Process &amp; Other Non‐Indexed Citations (2012 to February 2016).</p> </li> <li> <p>EMBASE (1980 to February 2016).</p> </li> <li> <p>Database of Abstracts and Reviews of Effects (1991 to April 2013).</p> </li> <li> <p>International Pharmaceutical Abstracts (1970 to April 2013).</p> </li> <li> <p>PsycINFO (1806 to April 2013).</p> </li> <li> <p>EBSCOhost CINAHL (Cumulative Index of Nursing and Allied Health) (1937 to April 2013).</p> </li> </ul> </p> <p>The search strategies used a combination of text words and medical subject headings (MeSH), adapted for each database searched: concepts included migraine, headache, cephalgia or cephalalgia, drug therapy, drug treatment, antimigraine therapy, antimigraine treatment, and treatment outcome, combined with drugs and acute treatments known to be used for migraine in children and adolescents. These terms were combined with a pediatric filter designed by the librarian (Lisa Tjosvold) of the Cochrane Child Health Field. </p> <p>Complete search strategies are given in <a href="./appendices#CD005220-sec-0077">Appendix 1</a>. </p> </section> <section id="CD005220-sec-0021"> <h4 class="title">Searching other resources</h4> <p>We conducted a gray literature search including reviewing the reference lists of included studies and handsearching meeting abstracts from the American Headache Society and International Headache Society Scientific meetings. The review authors attempted to contact primary authors, experts in the area, and drug manufacturers (GlaxoSmithKline, AstraZeneca, Ortho‐McNeil, Merck, and Pfizer) for information on recent, ongoing, or unpublished trials. We searched ClinicalTrials.gov for new or ongoing studies and used Current Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">www.controlled-trials.com</a>) to search across multiple trial registries. GlaxoSmithKline (<a href="http://www.gsk-clinicalstudyregister.com" target="_blank">www.gsk-clinicalstudyregister.com</a>) and AstraZeneca (<a href="http://www.astrazenecaclinicaltrials.com" target="_blank">www.astrazenecaclinicaltrials.com</a>) have clinical trial registries and report on both published and unpublished studies. </p> </section> </section> <section id="CD005220-sec-0022"> <h3 class="title" id="CD005220-sec-0022">Data collection and analysis</h3> <section id="CD005220-sec-0023"> <h4 class="title">Selection of studies</h4> <p>We identified potentially relevant articles by reviewing the titles and abstracts from the original search. We considered studies with insufficient information in the title or abstract as potentially relevant articles for further assessment. We then reviewed the full text of potentially relevant studies for inclusion or exclusion. Two reviewers independently carried out both steps. A third, independent reviewer resolved any disagreements that arose between them. </p> </section> <section id="CD005220-sec-0024"> <h4 class="title">Data extraction and management</h4> <p>One reviewer used a standardized data abstraction form to extract data, which a second reviewer then checked for accuracy and completeness. We recorded extracted data in Review Manager 5 (<a href="./references#CD005220-bbs2-0060" title="Review Manager. Version 5.3. The Nordic Cochrane Centre, Copenhagen: Cochrane, 2014.">RevMan 2014</a>). A third, independent reviewer resolved discrepancies. </p> </section> <section id="CD005220-sec-0025"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two reviewers assessed risk of bias using the 'Risk of bias' table for each study. Reviewers assessed five domains before making a judgement: sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting (<a href="./references#CD005220-bbs2-0048" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.">Higgins 2011</a>). We resolved any disagreements by discussion. We did not use the Jadad scale as planned in the protocol, as per current recommendations of the Cochrane Collaboration (<a href="#CD005220-sec-0085">Differences between protocol and review</a>). </p> </section> <section id="CD005220-sec-0026"> <h4 class="title">Assessment of quality of evidence in included studies</h4> <p>We assessed the overall quality of the evidence for each outcome using the GRADE system and included our assessment in the 'Summary of findings' tables in order to present the main findings of the review in a transparent and simple tabular format (<a href="./references#CD005220-bbs2-0045" title="GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.), 2015. Available from www.gradepro.org.">GRADEPro 2015</a>). In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the main outcomes. </p> <p>The GRADE system uses the following criteria for assigning a level of evidence.</p> <p> <ul id="CD005220-list-0003"> <li> <p>High: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low: any estimate of effect is very uncertain.</p> </li> </ul> </p> <p>We decreased the grade if we found:</p> <p> <ul id="CD005220-list-0004"> <li> <p>serious (− 1) or very serious (− 2) limitations to study quality;</p> </li> <li> <p>important inconsistency(s) (− 1);</p> </li> <li> <p>some (− 1) or major (− 2) uncertainty about directness;</p> </li> <li> <p>imprecise or sparse data (− 1);</p> </li> <li> <p>high probability of reporting bias (− 1).</p> </li> </ul> </p> </section> <section id="CD005220-sec-0027"> <h4 class="title">'Summary of findings' table</h4> <p>We decided <i>post hoc</i> to include four 'Summary of findings' tables to present the main findings in a transparent and simple tabular format. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes pain freedom at 2 hours and adverse events, for the four main comparisons. </p> </section> <section id="CD005220-sec-0028"> <h4 class="title">Measures of treatment effect</h4> <p>We reported the risk ratio (RR) for all primary and secondary efficacy outcome measures with 95% confidence intervals (CIs) as well as the number needed to treat for an additional beneficial outcome (NNTB). We reported the risk difference (RD) with 95% CIs for the adverse events as the primary measure of harm as well as the number needed to treat for an additional harmful outcome (NNTH). </p> </section> <section id="CD005220-sec-0029"> <h4 class="title">Unit of analysis issues</h4> <p>We included cross‐over trials with binary outcomes in the analysis (<a href="./references#CD005220-bbs2-0039" title="CurtinF , ElbourneD , AltmanDG . Meta-analysis combining parallel and cross-over clinical trials. II: binary outcomes. Statistics in Medicine2002;21(15):2145-59. [DOI: 10.1002/sim.1206]">Curtin 2002</a>). None of the cross‐over trials reported any significant carry‐over or period effects, and none would be expected based on the acute episodic nature of migraine. </p> </section> <section id="CD005220-sec-0030"> <h4 class="title">Dealing with missing data</h4> <p>We only analyzed the available data for all outcomes. We assessed the possibility of missing studies as described below (see <a href="#CD005220-sec-0032">Assessment of reporting biases</a>). We considered variability in the reporting of outcomes to be random. </p> </section> <section id="CD005220-sec-0031"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity using the I<sup>2</sup> statistic. We interpreted the I<sup>2</sup> statistic as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005220-bbs2-0048" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD005220-sec-0032"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting biases qualitatively by visually examining the funnel plot and quantitatively using a modified version of Egger's test (<a href="./references#CD005220-bbs2-0042" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629]">Egger 1997</a>; <a href="./references#CD005220-bbs2-0046" title="HarbordRM , EggerM , SterneJAC . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57. [DOI: 10.1002/sim.2380]">Harbord 2006</a>), as implemented in the metabias module for Stata statistical software package on the triptan versus placebo studies in adolescents using the pain‐free outcome (<a href="./references#CD005220-bbs2-0062" title="Stata Statistical Software: Release 14. StataCorp. College Station, TX: StataCorp LP, 2015.">Stata 14</a>). </p> </section> <section id="CD005220-sec-0033"> <h4 class="title">Data synthesis</h4> <p>We pooled studies using a Mantel‐Haenszel, random‐effects model. We pooled dichotomous outcomes, and calculated RRs with 95% CIs. We calculated the number needed to treat for an additional beneficial outcome (NNTB) for RRs of the primary outcome that were statistically significant. For adverse events, we combined data combined using RDs with 95% CIs. We calculated the number needed to treat for an additional harmful outcome (NNTH) for RDs of adverse events that were statistically significant. We included studies with small sample sizes and imprecise effect estimates, but we graded them lower for quality and weighted them accordingly in the meta‐analyses. </p> <p>We combined trials of cross‐over design with parallel group trials in the meta‐analysis. We included outcome measures from each intervention period in the analysis as if the trial were a parallel group trial. We also included three‐way cross‐over studies with two intervention periods and one placebo period as if they were a parallel group trial, but we divided the placebo period in two to avoid double counting the placebo interventions. Paired analysis was not possible for any of the included studies (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). This method of including cross‐over studies will tend to produce wider confidence intervals and is considered a more conservative assessment of treatment effect given that these studies will receive a lower weight in the meta‐analyses. We included study design in the sensitivity analysis to assess the influence of cross‐over design on our final conclusions. </p> </section> <section id="CD005220-sec-0034"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to determine the presence of heterogeneity and test for subgroup differences as implemented in RevMan, used to prepare this review (<a href="./references#CD005220-bbs2-0047" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [DOI: 10.1002/sim.1186]">Higgins 2002</a>; <a href="./references#CD005220-bbs2-0060" title="Review Manager. Version 5.3. The Nordic Cochrane Centre, Copenhagen: Cochrane, 2014.">RevMan 2014</a>). We performed all subgroup analyses for the pain‐free outcome measure using the placebo‐controlled studies of triptan medications versus placebo in adolescents (except for the age‐based subgroup analysis). </p> <p>Post hoc subgroup analyses included the following.</p> <p> <ol id="CD005220-list-0005"> <li> <p>Intranasal route.</p> </li> <li> <p>Preventive medication permitted during the study.</p> </li> </ol> </p> </section> <section id="CD005220-sec-0035"> <h4 class="title">Sensitivity analysis</h4> <p>We examined potential sources of heterogeneity using the following a priori sensitivity analyses (see <a href="#CD005220-sec-0085">Differences between protocol and review</a>). </p> <p> <ol id="CD005220-list-0006"> <li> <p>Allocation concealment (low, unclear, or high risk of bias).</p> </li> <li> <p>Cross‐over versus parallel‐group study design.</p> </li> <li> <p>Source of funding (pharmaceutical, non‐pharmaceutical, or unclear).</p> </li> <li> <p>Reported in a peer‐reviewed indexed journal.</p> </li> <li> <p>Small sample size ≤ 50.</p> </li> </ol> </p> <p>We performed all sensitivity analyses for the pain‐free primary outcome using the studies of triptan medications versus placebo in adolescents. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005220-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005220-sec-0036"></div> <section id="CD005220-sec-0037"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD005220-sec-0090" title="">Characteristics of included studies</a>, <a href="./references#CD005220-sec-0091" title="">Characteristics of excluded studies</a>, Characteristics of ongoing studies. </p> <section id="CD005220-sec-0038"> <h4 class="title">Results of the search</h4> <p>The literature search and review of the gray literature yielded 15,811 unique citations, 379 of which we assessed as full‐text articles for eligibility. Some of our data requests to manufacturers were met with referrals to trial registry websites or data were not made available. A total of 27 randomized placebo‐controlled trials of acute drug therapy for migraine met our inclusion criteria (<a href="#CD005220-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD005220-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005220-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD005220-sec-0039"> <h4 class="title">Included studies</h4> <p>The mean age of inclusion was 12.9 years with a range of means between 8.2 and 14.7 years. The minimum age of inclusion was 4 years in one study (<a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a>), and the maximum age for inclusion was 18 years in two studies (<a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a>; <a href="./references#CD005220-bbs2-0008" title="HämäläinenML , HoppuK , SantavuoriP . Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?Neurology1997;48(4):1100-3. [PMID: 9109909]">Hämäläinen 1997b</a>). Three studies included only children under 12 (<a href="./references#CD005220-bbs2-0010" title="HämäläinenM , JonesM , LoftusJ , SaiersJ . Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. International Journal of Clinical Practice2002;56(9):704-9. [PMID: 12469987]SUM30009. A single centre, placebo-controlled, double blind, randomised cross-over, single attack study evaluating the efficacy and tolerability of sumatriptan nasal spray 10 mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura. http://www.gsk-clinicalstudyregister.com/study/SUM30009#rs (accessed 24 June 2015). ">Hämäläinen 2002</a>; <a href="./references#CD005220-bbs2-0012" title="LewisDW , KellsteinD , DahlG , BurkeB , FrankLM , ToorS , et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache2002;42(8):780-6. [DOI: 10.1046/j.1526-4610.2002.02180.x]">Lewis 2002</a>; <a href="./references#CD005220-bbs2-0021" title="UeberallMA , WenzelD . Intranasal sumatriptan for the acute treatment of migraine in children. Neurology1999;52(7):1507-10. [PMID: 10227648]">Ueberall 1999</a>), and one study reported data for children and adolescents separately (<a href="./references#CD005220-bbs2-0011" title="HoTW , PearlmanE , LewisD , HämäläinenM , ConnorK , MichelsonD , et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Headache2012;32(10):750-65. [DOI: 10.1177/0333102412451358]">Ho 2012</a>). Six studies included children and adolescents, but they did not report the data separately (<a href="./references#CD005220-bbs2-0001" title="AhonenK , HämäläinenML , RantalaH , HoppuK . Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology2004;62(6):883-7. [DOI: 10.1212/01.WNL.0000115105.05966.A7]">Ahonen 2004</a>; <a href="./references#CD005220-bbs2-0002" title="AhonenK , HämäläinenML , EerolaM , HoppuK . A randomized trial of rizatriptan in migraine attacks in children. Neurology2006;67(7):1135-40. [DOI: 10.1212/01.wnl.0000238179.79888.44]">Ahonen 2006</a>; <a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a>; <a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a>; <a href="./references#CD005220-bbs2-0008" title="HämäläinenML , HoppuK , SantavuoriP . Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?Neurology1997;48(4):1100-3. [PMID: 9109909]">Hämäläinen 1997b</a>; <a href="./references#CD005220-bbs2-0009" title="HämäläinenM , HoppuK , SantavuoriPR . Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatric Neurology1997;16(2):114-7. [DOI: 10.1016/S0887-8994(96)00289-5]">Hämäläinen 1997c</a>). Participants in two of the studies reporting children and adolescents combined had a mean age of less than 12 years and were included in the analysis as studies of predominantly children (<a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a>; <a href="./references#CD005220-bbs2-0009" title="HämäläinenM , HoppuK , SantavuoriPR . Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatric Neurology1997;16(2):114-7. [DOI: 10.1016/S0887-8994(96)00289-5]">Hämäläinen 1997c</a>). Participants in the remaining four studies where children and adolescents were combined had a mean age of greater than 12 years, and we considered them to be studies of predominantly adolescents for the analysis. Finally, 17 studies included only adolescents over the age of 12 years (<a href="./references#CD005220-bbs2-0003" title="CallenbachPM , PelsLP , MulderPG , LinssenWH , GooskensRH , Van der ZwanJL , et al. Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children. European Journal of Paediatric Neurology2007;11(6):325-30. [DOI: 10.1016/j.ejpn.2007.02.010]SUM30042. A multi-centre, randomised, double-blind, placebo-controlled, cross-over study to investigate the efficacy, safety and tolerability of sumatriptan nasal spray (10mg or 20mg) in the treatment of migraine in patients aged 12-17. http://www.gsk-clinicalstudyregister.com/study/SUM30042#rs (accessed 24 June 2015). ">Callenbach 2007</a>; <a href="./references#CD005220-bbs2-0004" title="DerosierFJ , LewisD , HersheyAD , WinnerPK , PearlmanE , RothnerAD , et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics2012;129(6):e1411-20. [DOI: 10.1542/peds.2011-2455]">Derosier 2012</a>; <a href="./references#CD005220-bbs2-0006" title="FujitaM , SatoK , NishiokaH , SakaiF . Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia2014;34(5):365-75. [DOI: 10.1177/0333102413510213]SUM111035. A randomized, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral sumatriptan for the acute treatment of migraine in children and adolescents. http://www.gsk-clinicalstudyregister.com/study/111035#ps (accessed 24 June 2015). ">Fujita 2014</a>; <a href="./references#CD005220-bbs2-0013" title="LewisDW , WinnerP , HersheyAD , WaslewskiWW , Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics2007;120(2):390-6. [DOI: 10.1542/peds.2007-0085]">Lewis 2007</a>; <a href="./references#CD005220-bbs2-0014" title="LinderSL , MathewNT , CadyRK , FinlaysonG , IshkanianG , LewisDW . Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache2008;48(9):1326-36. [DOI: 10.1111/j.1526-4610.2008.01138.x]">Linder 2008</a>; <a href="./references#CD005220-bbs2-0015" title="NCT01211145. Zomig - treatment of acute migraine headache in adolescents (TEENZ). clinicaltrials.gov/ct2/show/NCT01211145 (accessed 24 June 2015). ">NCT01211145</a>; <a href="./references#CD005220-bbs2-0016" title="RothnerA , EdwardsK , KerrL , DeBusseyS , AsgharnejadM . Efficacy and safety of naratriptan tablets in adolescent migraine. Journal of Neurological Sciences1997;150(Suppl 1):S106. S2WA3012. A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population. http://www.gsk-clinicalstudyregister.com/study/S2WA3012#rs (accessed 24 June 2015). ">Rothner 1997</a>; <a href="./references#CD005220-bbs2-0017" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. SUMB2003. A double-blind, randomised, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg) in the acute treatment of migraine in adolescents. http://www.gsk-clinicalstudyregister.com/study/SUMB2003#rs (accessed 24 June 2015). ">Rothner 1999a</a>; <a href="./references#CD005220-bbs2-0018" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. ">Rothner 1999b</a>; <a href="./references#CD005220-bbs2-0019" title="RotherD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. [GSK ID: S2CT40]">Rothner 1999c</a>; <a href="./references#CD005220-bbs2-0020" title="RothnerAD , WasiewskiW , WinnerP , LewisD , StankowskiJ . Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache2006;46(1):101-9. [DOI: 10.1111/j.1526-4610.2006.00313.x]">Rothner 2006</a>; <a href="./references#CD005220-bbs2-0022" title="VisserWH , WinnerP , StrohmaierK , KlipfelM , PengY , McCarrollK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache2004;44:891-9. [DOI: 10.1111/j.1526-4610.2004.04171.x]">Visser 2004a</a>; <a href="./references#CD005220-bbs2-0023" title="WinnerP , PrenskyA , LinderS , DeBusseyS , AsgharnejadM . Adolescent migraine: efficacy and safety of sumatriptan tablets. Journal of the Neurological Sciences1997;150(Suppl 1):S172. [DOI: 10.1016/S0022-510X(97)85694-8]">Winner 1997</a>; <a href="./references#CD005220-bbs2-0024" title="WinnerP , RothnerAD , SaperJ , NettR , AsgharnejadM , LaurenzaA , et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics2000;106(5):989-97. [PMID: 11061765]">Winner 2000</a>; <a href="./references#CD005220-bbs2-0025" title="WinnerP , LewisD , VisserWH , JiangK , AhrensS , EvansJK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache2002;42(1):49-55. [DOI: 10.1046/j.1526-4610.2002.02013.x]">Winner 2002</a>; <a href="./references#CD005220-bbs2-0026" title="SUM30045. A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (5mg And 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 years of age). http://www.gsk-clinicalstudyregister.com/study/SUM30045#rs (accessed 24 June 2015). WinnerP , RothnerAD , WootenJD , WebsterC , AmesM . Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache2006;46(2):212-22. [DOI: 10.1111/j.1526-4610.2006.00339.x]WinnerP , RothnerD , WebsterCJ , AmesMH , KoriSH . Randomized, double-blind, placebo- controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology2004;62(7 Suppl 5):A182. ">Winner 2006</a>; <a href="./references#CD005220-bbs2-0027" title="PitmanV . Efficacy, safety and tolerability of oral eletriptan (40 mg) for the treatment of migraine in adolescents (12-17 years). Headache2000;40(5):424-5. WinnerP , LinerSL , LiptonRB , AlmasM , ParsonsB , PitmanV . Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache2007;47(4):511-8. [DOI: 10.1111/j.1526-4610.2007.00755.x]">Winner 2007</a>). The mean number of participants randomized was 359 with a range of 13 to 888. We summarize the characteristics of included studies in <a href="#CD005220-tbl-0005">Table 1</a>, and we summarize the individual studies in <a href="#CD005220-tbl-0006">Table 2</a>. We provide more details, including a risk of bias assessment, in <a href="./references#CD005220-sec-0090" title="">Characteristics of included studies</a>. </p> <div class="table" id="CD005220-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>N <b>= 27<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study design</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Sponsorship</b> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharmaceutical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐pharmaceutical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Age inclusion criteria</b> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adolescents (12‐17 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children (&lt; 12 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Pain scale</b> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐faces scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Preventive medication permitted?</b> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Route of delivery</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intranasal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Medications</b> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibuprofen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triptans</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>Triptan medications</b> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Almotriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eletriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naratriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rizatriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan + naproxen sodium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolmitriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>DHE</b> : dihydroergotamine; <b>VAS</b>: visual analogue scale. </p> <p><sup>a</sup>The total number of studies listed in Medications does not add up to 27 as two studies (<a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a> &amp; <a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a>) compared multiple medications. </p> </div> </div> <div class="table" id="CD005220-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary table of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review Manager ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Child.</b> </p> <p><b>(&lt; 12 yrs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adolesc.</b> </p> <p><b>(12‐17 yrs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>% Female</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Paracetamol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Ibuprofen</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0012" title="LewisDW , KellsteinD , DahlG , BurkeB , FrankLM , ToorS , et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache2002;42(8):780-6. [DOI: 10.1046/j.1526-4610.2002.02180.x]">Lewis 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Triptans (&lt; 12 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0011" title="HoTW , PearlmanE , LewisD , HämäläinenM , ConnorK , MichelsonD , et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Headache2012;32(10):750-65. [DOI: 10.1177/0333102412451358]">Ho 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0021" title="UeberallMA , WenzelD . Intranasal sumatriptan for the acute treatment of migraine in children. Neurology1999;52(7):1507-10. [PMID: 10227648]">Ueberall 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0010" title="HämäläinenM , JonesM , LoftusJ , SaiersJ . Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. International Journal of Clinical Practice2002;56(9):704-9. [PMID: 12469987]SUM30009. A single centre, placebo-controlled, double blind, randomised cross-over, single attack study evaluating the efficacy and tolerability of sumatriptan nasal spray 10 mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura. http://www.gsk-clinicalstudyregister.com/study/SUM30009#rs (accessed 24 June 2015). ">Hämäläinen 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Triptans (12‐17 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0014" title="LinderSL , MathewNT , CadyRK , FinlaysonG , IshkanianG , LewisDW . Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache2008;48(9):1326-36. [DOI: 10.1111/j.1526-4610.2008.01138.x]">Linder 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>60%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0027" title="PitmanV . Efficacy, safety and tolerability of oral eletriptan (40 mg) for the treatment of migraine in adolescents (12-17 years). Headache2000;40(5):424-5. WinnerP , LinerSL , LiptonRB , AlmasM , ParsonsB , PitmanV . Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache2007;47(4):511-8. [DOI: 10.1111/j.1526-4610.2007.00755.x]">Winner 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0016" title="RothnerA , EdwardsK , KerrL , DeBusseyS , AsgharnejadM . Efficacy and safety of naratriptan tablets in adolescent migraine. Journal of Neurological Sciences1997;150(Suppl 1):S106. S2WA3012. A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population. http://www.gsk-clinicalstudyregister.com/study/S2WA3012#rs (accessed 24 June 2015). ">Rothner 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0011" title="HoTW , PearlmanE , LewisD , HämäläinenM , ConnorK , MichelsonD , et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Headache2012;32(10):750-65. [DOI: 10.1177/0333102412451358]">Ho 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>61%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0022" title="VisserWH , WinnerP , StrohmaierK , KlipfelM , PengY , McCarrollK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache2004;44:891-9. [DOI: 10.1111/j.1526-4610.2004.04171.x]">Visser 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>55%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0025" title="WinnerP , LewisD , VisserWH , JiangK , AhrensS , EvansJK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache2002;42(1):49-55. [DOI: 10.1046/j.1526-4610.2002.02013.x]">Winner 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0002" title="AhonenK , HämäläinenML , EerolaM , HoppuK . A randomized trial of rizatriptan in migraine attacks in children. Neurology2006;67(7):1135-40. [DOI: 10.1212/01.wnl.0000238179.79888.44]">Ahonen 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0003" title="CallenbachPM , PelsLP , MulderPG , LinssenWH , GooskensRH , Van der ZwanJL , et al. Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children. European Journal of Paediatric Neurology2007;11(6):325-30. [DOI: 10.1016/j.ejpn.2007.02.010]SUM30042. A multi-centre, randomised, double-blind, placebo-controlled, cross-over study to investigate the efficacy, safety and tolerability of sumatriptan nasal spray (10mg or 20mg) in the treatment of migraine in patients aged 12-17. http://www.gsk-clinicalstudyregister.com/study/SUM30042#rs (accessed 24 June 2015). ">Callenbach 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>78%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0018" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. ">Rothner 1999b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>52%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0024" title="WinnerP , RothnerAD , SaperJ , NettR , AsgharnejadM , LaurenzaA , et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics2000;106(5):989-97. [PMID: 11061765]">Winner 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>52%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0008" title="HämäläinenML , HoppuK , SantavuoriP . Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?Neurology1997;48(4):1100-3. [PMID: 9109909]">Hämäläinen 1997b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>52%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0019" title="RotherD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. [GSK ID: S2CT40]">Rothner 1999c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>42%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0006" title="FujitaM , SatoK , NishiokaH , SakaiF . Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia2014;34(5):365-75. [DOI: 10.1177/0333102413510213]SUM111035. A randomized, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral sumatriptan for the acute treatment of migraine in children and adolescents. http://www.gsk-clinicalstudyregister.com/study/111035#ps (accessed 24 June 2015). ">Fujita 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>58%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0023" title="WinnerP , PrenskyA , LinderS , DeBusseyS , AsgharnejadM . Adolescent migraine: efficacy and safety of sumatriptan tablets. Journal of the Neurological Sciences1997;150(Suppl 1):S172. [DOI: 10.1016/S0022-510X(97)85694-8]">Winner 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>58%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0026" title="SUM30045. A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (5mg And 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 years of age). http://www.gsk-clinicalstudyregister.com/study/SUM30045#rs (accessed 24 June 2015). WinnerP , RothnerAD , WootenJD , WebsterC , AmesM . Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache2006;46(2):212-22. [DOI: 10.1111/j.1526-4610.2006.00339.x]WinnerP , RothnerD , WebsterCJ , AmesMH , KoriSH . Randomized, double-blind, placebo- controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology2004;62(7 Suppl 5):A182. ">Winner 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>55%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0001" title="AhonenK , HämäläinenML , RantalaH , HoppuK . Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology2004;62(6):883-7. [DOI: 10.1212/01.WNL.0000115105.05966.A7]">Ahonen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>46%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0017" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. SUMB2003. A double-blind, randomised, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg) in the acute treatment of migraine in adolescents. http://www.gsk-clinicalstudyregister.com/study/SUMB2003#rs (accessed 24 June 2015). ">Rothner 1999a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0004" title="DerosierFJ , LewisD , HersheyAD , WinnerPK , PearlmanE , RothnerAD , et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics2012;129(6):e1411-20. [DOI: 10.1542/peds.2011-2455]">Derosier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan and</p> <p>Naproxen Sodium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0013" title="LewisDW , WinnerP , HersheyAD , WaslewskiWW , Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics2007;120(2):390-6. [DOI: 10.1542/peds.2007-0085]">Lewis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0020" title="RothnerAD , WasiewskiW , WinnerP , LewisD , StankowskiJ . Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache2006;46(1):101-9. [DOI: 10.1111/j.1526-4610.2006.00313.x]">Rothner 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0015" title="NCT01211145. Zomig - treatment of acute migraine headache in adolescents (TEENZ). clinicaltrials.gov/ct2/show/NCT01211145 (accessed 24 June 2015). ">NCT01211145</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Dihydroergotamine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0009" title="HämäläinenM , HoppuK , SantavuoriPR . Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatric Neurology1997;16(2):114-7. [DOI: 10.1016/S0887-8994(96)00289-5]">Hämäläinen 1997c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>38%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IN: intranasal; NA: not applicable; ND: no data available; No: total number in efficacy analysis (intention‐to‐treat when available); PO: per os (by mouth). </p> </div> </div> </section> <section id="CD005220-sec-0040"> <h4 class="title">Excluded studies</h4> <p>We excluded two studies, one that compared intravenous prochlorperazine versus ketorolac in children and adolescents presenting to the Emergency Department (ED) (<a href="./references#CD005220-bbs2-0028" title="BrousseauDC , DuffySJ , AndersonAC , LinakisJG . Treatment of pediatric migraines: a randomized, double-blind trial of prochlorperazine versus ketorolac. Annals of Emergency Medicine2004;43(2):256-62. [DOI: 10.1016/S0196-0644(03)00716-9]">Brousseau 2004</a>) and one that compared intravenous metoclopramide to placebo in children and adolescents presenting to the ED (<a href="./references#CD005220-bbs2-0031" title="NCT00355394. Treatment of acute migraine headache in children. clinicaltrials.gov/show/NCT00355394 (accessed 3 February 2016). ">NCT00355394</a>) from the analysis as our review is focused on outpatient acute drug therapy. All other excluded studies were either not controlled or were non‐drug clinical trials (see <a href="./references#CD005220-sec-0091" title="">Characteristics of excluded studies</a>). </p> </section> <section id="CD005220-sec-0041"> <h4 class="title">Awaiting classification</h4> <p>A single study was recently published and is awaiting classification (<a href="./references#CD005220-bbs2-0036" title="NCT01016678. Treximet Early Intervention Adolescent Migraine (TEAM). clinicaltrials.gov/ct2/show/NCT01016678 (accessed 24 June 2015). WinnerP , LinderS , HersheyAD . Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescents. Headache2015;55:519-28. [DOI: 10.1111/head.12555]">Winner 2015</a>). It is a cross‐over study of sumatriptan + naproxen sodium in adolescents (see <a href="./references#CD005220-sec-0092" title="">Characteristics of studies awaiting classification</a>). </p> </section> </section> <section id="CD005220-sec-0042"> <h3 class="title">Risk of bias in included studies</h3> <p>We illustrated the risk of bias in included studies in <a href="#CD005220-fig-0002">Figure 2</a> and <a href="#CD005220-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD005220-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005220-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005220-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005220-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005220-sec-0043"> <h4 class="title">Allocation</h4> <p>Investigators described all studies as randomized (low risk of selection bias (random sequence generation)), but the method of randomization was unclear in 19 studies (unclear risk of bias). Authors frequently employed generic descriptions of sequence generation such as 'randomized 1:1' or 'block randomization to two age groups'. Eight studies adequately reported allocation concealment, and we judged them to be at low risk of selection bias (allocation concealment). We judged the remaining 19 studies to be at unclear risk of bias for this domain. </p> </section> <section id="CD005220-sec-0044"> <h4 class="title">Blinding</h4> <p>Generally, authors described all studies as double‐blind, but 17 studies did not report their methods for blinding clearly (unclear risk of bias). All studies were either an oral or intranasal medication compared with placebo. Studies seldom described efforts to match for taste, color, smell, etc. We considered 10 studies to be at low risk of bias. </p> </section> <section id="CD005220-sec-0045"> <h4 class="title">Incomplete outcome data</h4> <p>We considered incomplete reporting of outcome data to confer a high risk of bias in <a href="./references#CD005220-bbs2-0025" title="WinnerP , LewisD , VisserWH , JiangK , AhrensS , EvansJK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache2002;42(1):49-55. [DOI: 10.1046/j.1526-4610.2002.02013.x]">Winner 2002</a> and an unclear risk in <a href="./references#CD005220-bbs2-0009" title="HämäläinenM , HoppuK , SantavuoriPR . Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatric Neurology1997;16(2):114-7. [DOI: 10.1016/S0887-8994(96)00289-5]">Hämäläinen 1997c</a>. We considered the remaining 25 studies to be at low risk. </p> </section> <section id="CD005220-sec-0046"> <h4 class="title">Selective reporting</h4> <p>Six studies were reported only in the sponsors' clinical trial report registry and published only in abstract form (<a href="./references#CD005220-bbs2-0010" title="HämäläinenM , JonesM , LoftusJ , SaiersJ . Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. International Journal of Clinical Practice2002;56(9):704-9. [PMID: 12469987]SUM30009. A single centre, placebo-controlled, double blind, randomised cross-over, single attack study evaluating the efficacy and tolerability of sumatriptan nasal spray 10 mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura. http://www.gsk-clinicalstudyregister.com/study/SUM30009#rs (accessed 24 June 2015). ">Hämäläinen 2002</a>; <a href="./references#CD005220-bbs2-0016" title="RothnerA , EdwardsK , KerrL , DeBusseyS , AsgharnejadM . Efficacy and safety of naratriptan tablets in adolescent migraine. Journal of Neurological Sciences1997;150(Suppl 1):S106. S2WA3012. A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population. http://www.gsk-clinicalstudyregister.com/study/S2WA3012#rs (accessed 24 June 2015). ">Rothner 1997</a>; <a href="./references#CD005220-bbs2-0017" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. SUMB2003. A double-blind, randomised, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg) in the acute treatment of migraine in adolescents. http://www.gsk-clinicalstudyregister.com/study/SUMB2003#rs (accessed 24 June 2015). ">Rothner 1999a</a>; <a href="./references#CD005220-bbs2-0018" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. ">Rothner 1999b</a>; <a href="./references#CD005220-bbs2-0019" title="RotherD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. [GSK ID: S2CT40]">Rothner 1999c</a>; <a href="./references#CD005220-bbs2-0023" title="WinnerP , PrenskyA , LinderS , DeBusseyS , AsgharnejadM . Adolescent migraine: efficacy and safety of sumatriptan tablets. Journal of the Neurological Sciences1997;150(Suppl 1):S172. [DOI: 10.1016/S0022-510X(97)85694-8]">Winner 1997</a>), while one study was reported only in the sponsor's clinical trial report registry (<a href="./references#CD005220-bbs2-0015" title="NCT01211145. Zomig - treatment of acute migraine headache in adolescents (TEENZ). clinicaltrials.gov/ct2/show/NCT01211145 (accessed 24 June 2015). ">NCT01211145</a>). All included studies reported the pain‐free primary efficacy outcome. The reports available through the sponsors' clinical trial registries were comprehensive in reporting all planned outcome measures and greatly enhanced the reported data that was published in abstract form. Also, there were no discrepancies between published abstracts and the reports released through the sponsor's clinical trial registry. <a href="./references#CD005220-bbs2-0004" title="DerosierFJ , LewisD , HersheyAD , WinnerPK , PearlmanE , RothnerAD , et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics2012;129(6):e1411-20. [DOI: 10.1542/peds.2011-2455]">Derosier 2012</a> was the only study that did not report the headache relief secondary outcome, and <a href="./references#CD005220-bbs2-0012" title="LewisDW , KellsteinD , DahlG , BurkeB , FrankLM , ToorS , et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache2002;42(8):780-6. [DOI: 10.1046/j.1526-4610.2002.02180.x]">Lewis 2002</a> did not report adverse event data; we judged these two studies to be at unclear risk of bias for this domain. We judged the remaining 25 studies to be at low risk of bias. </p> </section> <section id="CD005220-sec-0047"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed publication bias based on the pain‐free outcome for all triptans versus placebo in adolescents. On visual inspection, the funnel plot showed some asymmetry (<a href="#CD005220-fig-0004">Figure 4</a>), suggesting the possibility of publication or other sources of bias and small‐study effects. We used Egger's test to explore small‐study effects, which were not significant (P = 0.139). The inclusion of published and unpublished data from the clinical trial registries would suggest a reduced risk of publication bias, as many of these studies were negative. </p> <div class="figure" id="CD005220-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 7 Triptans vs placebo in Adolescents, outcome: 7.1 Pain‐free." data-id="CD005220-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 7 Triptans vs placebo in Adolescents, outcome: 7.1 Pain‐free.</p> </div> </div> </div> </section> </section> <section id="CD005220-sec-0048"> <h3 class="title" id="CD005220-sec-0048">Effects of interventions</h3> <p>See: <a href="./full#CD005220-tbl-0001"><b>Summary of findings 1</b> Should ibuprofen be used to treat children with migraine?</a>; <a href="./full#CD005220-tbl-0002"><b>Summary of findings 2</b> Should triptans be used to treat children with migraine?</a>; <a href="./full#CD005220-tbl-0003"><b>Summary of findings 3</b> Should triptans be used to treat adolescents with migraine?</a>; <a href="./full#CD005220-tbl-0004"><b>Summary of findings 4</b> Should sumatriptan plus naproxen sodium be used to treat adolescents with migraine?</a> </p> <p>We describe the measures of effect for each of the interventions below. In addition, we present 'Summary of findings' tables for all comparisons for which there was more than one study. </p> <section id="CD005220-sec-0049"> <h4 class="title">Paracetamol versus placebo in children</h4> <p>In the one three‐way cross‐over study that evaluated paracetamol (<a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a>), the participant age ranged from 4 to 15.8 years (N = 88), but investigators did not report results for children and adolescents separately. However, the mean age of inclusion was 10.7 years, so we deemed the study to be predominantly in children. Paracetamol was not superior to placebo for the pain‐free outcome ( RR 1.40, 95% CI 0.75 to 2.58). There was no statistically significant difference in headache relief (defined as a reduction in pain by two grades on a five point scale), rescue medication, headache recurrence, or adverse events. The study did not report the presence of nausea or vomiting. </p> </section> <section id="CD005220-sec-0050"> <h4 class="title">Ibuprofen versus placebo in children</h4> <p>Ibuprofen was superior to placebo in the pooled analysis of two studies (<a href="#CD005220-fig-0005">Figure 5</a>) ‐ <a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a> was a three‐way cross‐over study with paracetamol, with a mean participant age of 10.7 years (N = 88), and <a href="./references#CD005220-bbs2-0012" title="LewisDW , KellsteinD , DahlG , BurkeB , FrankLM , ToorS , et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache2002;42(8):780-6. [DOI: 10.1046/j.1526-4610.2002.02180.x]">Lewis 2002</a> was a parallel group study that included only 6 to 12 year‐olds with a mean age of 9 years (N = 84). For the pain‐free primary outcome, the RR was 1.87 (95% CI 1.15 to 3.04; <a href="./references#CD005220-fig-0007" title="">Analysis 1.1</a>) with a NNTB of 4. Ibuprofen was also superior to placebo for headache relief (<a href="./references#CD005220-fig-0009" title="">Analysis 1.3</a>) but not for rescue medication (<a href="./references#CD005220-fig-0010" title="">Analysis 1.4</a>) or headache recurrence (<a href="./references#CD005220-fig-0011" title="">Analysis 1.5</a>). There was no difference in the proportion of adverse events between groups (<a href="./references#CD005220-fig-0008" title="">Analysis 1.2</a>). <a href="./references#CD005220-bbs2-0012" title="LewisDW , KellsteinD , DahlG , BurkeB , FrankLM , ToorS , et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache2002;42(8):780-6. [DOI: 10.1046/j.1526-4610.2002.02180.x]">Lewis 2002</a> did not report adverse events, and <a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a> did not report on the presence of nausea and vomiting. </p> <div class="figure" id="CD005220-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Ibuprofen vs placebo in Children, outcome: 2.1 Pain‐free." data-id="CD005220-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ibuprofen vs placebo in Children, outcome: 2.1 Pain‐free.</p> </div> </div> </div> <p>The quality of evidence for the pain‐free outcome was low, downgraded by two levels due to very serious imprecision (<a href="./full#CD005220-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD005220-sec-0051"> <h4 class="title">Ibuprofen versus placebo in adolescents</h4> <p>One small three‐way cross‐over study examined ibuprofen, zolmitriptan, and placebo (<a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a>). While it included both children and adolescents, the mean participant age was 13.9 years (N = 29), so we considered the study to be predominantly in adolescents. Headache relief at two hours was the primary outcome measure reported, but investigators also reported pain freedom at two hours. The pain‐free outcome was not statistically significant (RR 7.00, 95% CI 0.99 to 49.69), but ibuprofen was statistically superior to placebo for headache relief (RR 2.50, 95% CI 1.02 to 6.10). There were no significant differences in other secondary outcome measures, including use of rescue medication, headache recurrence, presence of nausea, or presence of vomiting. There was no significant difference in adverse events observed. </p> </section> <section id="CD005220-sec-0052"> <h4 class="title">Triptans versus placebo in children</h4> <p>Three studies examined two triptan medications in children under 12 years of age: rizatriptan (<a href="./references#CD005220-bbs2-0011" title="HoTW , PearlmanE , LewisD , HämäläinenM , ConnorK , MichelsonD , et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Headache2012;32(10):750-65. [DOI: 10.1177/0333102412451358]">Ho 2012</a>, N = 200) and sumatriptan (<a href="./references#CD005220-bbs2-0010" title="HämäläinenM , JonesM , LoftusJ , SaiersJ . Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. International Journal of Clinical Practice2002;56(9):704-9. [PMID: 12469987]SUM30009. A single centre, placebo-controlled, double blind, randomised cross-over, single attack study evaluating the efficacy and tolerability of sumatriptan nasal spray 10 mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura. http://www.gsk-clinicalstudyregister.com/study/SUM30009#rs (accessed 24 June 2015). ">Hämäläinen 2002</a>, N = 59; <a href="./references#CD005220-bbs2-0021" title="UeberallMA , WenzelD . Intranasal sumatriptan for the acute treatment of migraine in children. Neurology1999;52(7):1507-10. [PMID: 10227648]">Ueberall 1999</a>, N = 14). Triptans as a class of medication were superior to placebo in children for the primary outcome measure of pain freedom (RR 1.67, 95% CI 1.06 to 2.62; <a href="./references#CD005220-fig-0012" title="">Analysis 2.1</a>) with a NNTB of 13. There were no statistically significant differences in the effect size between rizatriptan and sumatriptan subgroups. Overall, we did not observe any statistically significant difference in the secondary outcomes of headache relief (<a href="./references#CD005220-fig-0014" title="">Analysis 2.3</a>), rescue medication (<a href="./references#CD005220-fig-0015" title="">Analysis 2.4</a>), headache recurrence (<a href="./references#CD005220-fig-0016" title="">Analysis 2.5</a>), presence of nausea (<a href="./references#CD005220-fig-0017" title="">Analysis 2.6</a>), or presence of vomiting (<a href="./references#CD005220-fig-0018" title="">Analysis 2.7</a>). There was no statistically significant difference in the proportion of adverse events observed in the triptan versus placebo groups (<a href="./references#CD005220-fig-0013" title="">Analysis 2.2</a>). </p> <p>The quality of evidence for the pain‐free outcome was moderate, downgraded by one level due to serious imprecision (<a href="./full#CD005220-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD005220-sec-0053"> <h4 class="title">Triptans versus placebo in adolescents</h4> <p>Triptans as a class of medications were superior to placebo in adolescents for the acute treatment of migraine (<a href="#CD005220-fig-0006">Figure 6</a>). Overall the pain‐free RR was 1.32 (95% CI 1.19 to 1.47; <a href="./references#CD005220-fig-0019" title="">Analysis 3.1</a>) with a NNTB of 6 and low (I<sup>2</sup> = 26%), non‐significant heterogeneity (P = 0.13) between studies. Triptans for which there were two or more studies were statistically superior to placebo as a subgroup (<a href="#CD005220-fig-0006">Figure 6</a>), but subgroup differences in effect size were not statistically significant. The individual triptans included were almotriptan (<a href="./references#CD005220-bbs2-0014" title="LinderSL , MathewNT , CadyRK , FinlaysonG , IshkanianG , LewisDW . Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache2008;48(9):1326-36. [DOI: 10.1111/j.1526-4610.2008.01138.x]">Linder 2008</a>, N = 714), eletriptan (<a href="./references#CD005220-bbs2-0027" title="PitmanV . Efficacy, safety and tolerability of oral eletriptan (40 mg) for the treatment of migraine in adolescents (12-17 years). Headache2000;40(5):424-5. WinnerP , LinerSL , LiptonRB , AlmasM , ParsonsB , PitmanV . Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache2007;47(4):511-8. [DOI: 10.1111/j.1526-4610.2007.00755.x]">Winner 2007</a>, N = 274), naratriptan (<a href="./references#CD005220-bbs2-0016" title="RothnerA , EdwardsK , KerrL , DeBusseyS , AsgharnejadM . Efficacy and safety of naratriptan tablets in adolescent migraine. Journal of Neurological Sciences1997;150(Suppl 1):S106. S2WA3012. A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population. http://www.gsk-clinicalstudyregister.com/study/S2WA3012#rs (accessed 24 June 2015). ">Rothner 1997</a>, N = 300), rizatriptan (<a href="./references#CD005220-bbs2-0002" title="AhonenK , HämäläinenML , EerolaM , HoppuK . A randomized trial of rizatriptan in migraine attacks in children. Neurology2006;67(7):1135-40. [DOI: 10.1212/01.wnl.0000238179.79888.44]">Ahonen 2006</a>, N = 96; <a href="./references#CD005220-bbs2-0025" title="WinnerP , LewisD , VisserWH , JiangK , AhrensS , EvansJK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache2002;42(1):49-55. [DOI: 10.1046/j.1526-4610.2002.02013.x]">Winner 2002</a>, N = 296; <a href="./references#CD005220-bbs2-0011" title="HoTW , PearlmanE , LewisD , HämäläinenM , ConnorK , MichelsonD , et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Headache2012;32(10):750-65. [DOI: 10.1177/0333102412451358]">Ho 2012</a>, N = 570; <a href="./references#CD005220-bbs2-0022" title="VisserWH , WinnerP , StrohmaierK , KlipfelM , PengY , McCarrollK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache2004;44:891-9. [DOI: 10.1111/j.1526-4610.2004.04171.x]">Visser 2004a</a>, N = 476), sumatriptan (<a href="./references#CD005220-bbs2-0001" title="AhonenK , HämäläinenML , RantalaH , HoppuK . Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology2004;62(6):883-7. [DOI: 10.1212/01.WNL.0000115105.05966.A7]">Ahonen 2004</a>, N = 83; <a href="./references#CD005220-bbs2-0003" title="CallenbachPM , PelsLP , MulderPG , LinssenWH , GooskensRH , Van der ZwanJL , et al. Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children. European Journal of Paediatric Neurology2007;11(6):325-30. [DOI: 10.1016/j.ejpn.2007.02.010]SUM30042. A multi-centre, randomised, double-blind, placebo-controlled, cross-over study to investigate the efficacy, safety and tolerability of sumatriptan nasal spray (10mg or 20mg) in the treatment of migraine in patients aged 12-17. http://www.gsk-clinicalstudyregister.com/study/SUM30042#rs (accessed 24 June 2015). ">Callenbach 2007</a>, N = 46; <a href="./references#CD005220-bbs2-0006" title="FujitaM , SatoK , NishiokaH , SakaiF . Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia2014;34(5):365-75. [DOI: 10.1177/0333102413510213]SUM111035. A randomized, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral sumatriptan for the acute treatment of migraine in children and adolescents. http://www.gsk-clinicalstudyregister.com/study/111035#ps (accessed 24 June 2015). ">Fujita 2014</a>, N = 144; <a href="./references#CD005220-bbs2-0008" title="HämäläinenML , HoppuK , SantavuoriP . Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?Neurology1997;48(4):1100-3. [PMID: 9109909]">Hämäläinen 1997b</a>, N = 23; <a href="./references#CD005220-bbs2-0017" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. SUMB2003. A double-blind, randomised, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg) in the acute treatment of migraine in adolescents. http://www.gsk-clinicalstudyregister.com/study/SUMB2003#rs (accessed 24 June 2015). ">Rothner 1999a</a>, N = 273; <a href="./references#CD005220-bbs2-0018" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. ">Rothner 1999b</a>, N = 92; <a href="./references#CD005220-bbs2-0019" title="RotherD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. [GSK ID: S2CT40]">Rothner 1999c</a>, N = 102; <a href="./references#CD005220-bbs2-0023" title="WinnerP , PrenskyA , LinderS , DeBusseyS , AsgharnejadM . Adolescent migraine: efficacy and safety of sumatriptan tablets. Journal of the Neurological Sciences1997;150(Suppl 1):S172. [DOI: 10.1016/S0022-510X(97)85694-8]">Winner 1997</a>, N = 298; <a href="./references#CD005220-bbs2-0024" title="WinnerP , RothnerAD , SaperJ , NettR , AsgharnejadM , LaurenzaA , et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics2000;106(5):989-97. [PMID: 11061765]">Winner 2000</a>, N = 507; <a href="./references#CD005220-bbs2-0026" title="SUM30045. A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (5mg And 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 years of age). http://www.gsk-clinicalstudyregister.com/study/SUM30045#rs (accessed 24 June 2015). WinnerP , RothnerAD , WootenJD , WebsterC , AmesM . Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache2006;46(2):212-22. [DOI: 10.1111/j.1526-4610.2006.00339.x]WinnerP , RothnerD , WebsterCJ , AmesMH , KoriSH . Randomized, double-blind, placebo- controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology2004;62(7 Suppl 5):A182. ">Winner 2006</a>, N = 731), and zolmitriptan (<a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a>, N = 29; <a href="./references#CD005220-bbs2-0013" title="LewisDW , WinnerP , HersheyAD , WaslewskiWW , Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics2007;120(2):390-6. [DOI: 10.1542/peds.2007-0085]">Lewis 2007</a>, N = 171; <a href="./references#CD005220-bbs2-0015" title="NCT01211145. Zomig - treatment of acute migraine headache in adolescents (TEENZ). clinicaltrials.gov/ct2/show/NCT01211145 (accessed 24 June 2015). ">NCT01211145</a>, N = 584; <a href="./references#CD005220-bbs2-0020" title="RothnerAD , WasiewskiW , WinnerP , LewisD , StankowskiJ . Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache2006;46(1):101-9. [DOI: 10.1111/j.1526-4610.2006.00313.x]">Rothner 2006</a>, N = 696). There was, however, an increased risk of minor (non‐serious) adverse events in the triptan group when compared with placebo, with an RD of 0.13 (95% CI 0.08 to 0.18; <a href="./references#CD005220-fig-0020" title="">Analysis 3.2</a>) and NNTH of 8. The secondary efficacy outcomes that favoured triptans were headache relief (RR 1.14, 95% CI 1.04 to 1.24; <a href="./references#CD005220-fig-0021" title="">Analysis 3.3</a>), a reduction in the use of rescue medication (RR 0.79, 95% CI 0.72 to 0.87; <a href="./references#CD005220-fig-0022" title="">Analysis 3.4</a>), and reduced risk of headache recurrence (RR 0.79, 95% CI 0.68 to 0.93; <a href="./references#CD005220-fig-0023" title="">Analysis 3.5</a>). There were no statistically significant differences in the presence of nausea (<a href="./references#CD005220-fig-0024" title="">Analysis 3.6</a>) or vomiting (<a href="./references#CD005220-fig-0025" title="">Analysis 3.7</a>). </p> <div class="figure" id="CD005220-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 7 Triptans vs placebo in Adolescents, outcome: 7.1 Pain‐free." data-id="CD005220-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 7 Triptans vs placebo in Adolescents, outcome: 7.1 Pain‐free.</p> </div> </div> </div> <p>The quality of evidence for the pain‐free outcome was moderate, downgraded by one level due to serious inconsistency (<a href="./full#CD005220-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD005220-sec-0054"> <h4 class="title">Sumatriptan plus naproxen sodium versus placebo in adolescents</h4> <p>We included one study of sumatriptan plus naproxen sodium versus placebo. The study included adolescents with a mean age of 14.7 years and randomized a total of 683 participants. The doses of sumatriptan + naproxen sodium, respectively, were 10 mg + 60 mg (N = 96), 30 mg + 180 mg (N = 97), and 85 mg + 500 mg (N = 152). The primary outcome reported was pain freedom at two hours, with data adjusted for age and baseline severity. The adjusted pain‐free rates at two hours were higher with sumatriptan + naproxen sodium 10 mg + 60 mg (29%; adjusted P = 0.003), 30 mg + 180 mg (27%; adjusted P = 0.003), and 85 mg + 500 mg (24%; adjusted P = 0.003) versus placebo (10%). Post hoc analyses showed no differences among the 3 doses or an age‐by‐treatment interaction. Calculating the RR for pain relief at 2 hours, sumatriptan + naproxen sodium was superior to placebo with an RR of 3.25 (95% CI 1.78 to 5.94) and NNTB of 6. The use of rescue medication was also significantly reduced with the combination medication when compared with placebo (RR 0.46, 95% CI 0.32 to 0.64), but investigators did not report headache relief. There was no statistically significant increase in adverse events and no difference in the presence of nausea. Headache recurrence and presence of vomiting were also not reported. </p> <p>The quality of evidence for the pain‐free outcome was moderate, downgraded by one level due to the width of the confidence interval of the effect size (<a href="./full#CD005220-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD005220-sec-0055"> <h4 class="title">Dihydroergotamine (DHE) versus placebo in children</h4> <p>One small cross‐over study of dihydroergotamine versus placebo included children and adolescents aged 5 to 15 years (<a href="./references#CD005220-bbs2-0009" title="HämäläinenM , HoppuK , SantavuoriPR . Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatric Neurology1997;16(2):114-7. [DOI: 10.1016/S0887-8994(96)00289-5]">Hämäläinen 1997c</a>, N = 13). With a mean participant age of 10.3 years, we considered the study to be predominantly in children. DHE demonstrated no significant difference in the pain‐free outcome or any of the secondary outcomes, including headache relief or the use of rescue medications. There was no statistically significant increase in the proportion of adverse events between DHE and placebo. Authors did not report headache recurrence, presence of nausea, or the presence of vomiting. </p> </section> <section id="CD005220-sec-0056"> <h4 class="title">Subgroup analysis for other sources of heterogeneity</h4> <p>We assessed potentially important sources of clinical heterogeneity using the pain‐free outcome of triptan studies in adolescents. Tests for subgroup differences showed that effect size estimates for intranasal studies of sumatriptan and zolmitriptan were significantly higher than oral triptan studies of almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan (P = 0.02, I<sup>2</sup> = 81.5%, <a href="./references#CD005220-fig-0026" title="">Analysis 4.1</a>). We observed a statistically significant difference in the comparison of oral versus intranasal zolmitriptan studies, where intranasal delivery was associated with a significantly higher effect size for the pain‐free outcome (P = 0.04)=, I<sup>2</sup> = 77.1%; <a href="./references#CD005220-fig-0028" title="">Analysis 4.3</a>). However, the difference was not statistically significant when comparing oral versus intranasal sumatriptan studies (<a href="./references#CD005220-fig-0027" title="">Analysis 4.2</a>). The permitted concomitant use of migraine preventive medications in the triptan trials among adolescents was not associated with any significant difference in the effect size (<a href="./references#CD005220-fig-0029" title="">Analysis 4.4</a>). We did not observe any statistically significant differences in the overall effect size estimates between the triptan versus placebo studies that included only children, those where children and adolescents were mixed and not reported separately, and those studies that examined adolescents exclusively (P = 0.42, I<sup>2</sup> = 0%; <a href="./references#CD005220-fig-0030" title="">Analysis 5.1</a>). </p> </section> <section id="CD005220-sec-0057"> <h4 class="title">Sensitivity analysis of other study characteristics</h4> <p>The overall heterogeneity was low for the triptan versus placebo studies in adolescents for the pain‐free outcome (Tau<sup>2</sup> = 0.01; Chi<sup>2</sup> = 27.15, degrees of freedom (df) = 20 (P = 0.13); I<sup>2</sup> = 26%). We performed a sensitivity analysis to explore the effects of sponsorship; risk of bias in allocation concealment; study design (cross‐over versus parallel group); type of study report (journal article versus clinical trial registry and abstract); and small sample size (&lt; 50). The cross‐over study design was associated with significantly higher effect size estimates for the pain‐free outcome (P = 0.004, I<sup>2</sup> = 88.2%; <a href="./references#CD005220-fig-0031" title="">Analysis 6.1</a>). The effect estimate for the triptan versus placebo studies in adolescents was similar in direction, magnitude, and significance (i.e. RR 1.25, 95% CI 1.12 to 1.39) when we removed studies of cross‐over design. Similarly studies with a sample size of less than 50 had a significantly higher estimates of treatment effect (P = 0.03, I<sup>2</sup> = 79.4%; <a href="./references#CD005220-fig-0035" title="">Analysis 6.5</a>). The overall effect estimate without studies having small sample sizes was similar to the reported effect estimate (RR 1.31, 95% CI 1.18 to 1.46). There were no significant subgroup difference for allocation concealment (<a href="./references#CD005220-fig-0032" title="">Analysis 6.2</a>), source of funding (<a href="./references#CD005220-fig-0033" title="">Analysis 6.3</a>), or type of study report (<a href="./references#CD005220-fig-0034" title="">Analysis 6.4</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005220-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005220-sec-0058"></div> <section id="CD005220-sec-0059"> <h3 class="title" id="CD005220-sec-0059">Summary of main results</h3> <p>In total, we identified 27 moderate quality studies for inclusion. Most were at a low or unclear risk of bias and of varying size (a range of 13 to 888 participants in total). The mean age of inclusion was 12.9 years with a range of means between 8.2 and 14.7 years. </p> <section id="CD005220-sec-0060"> <h4 class="title">Paracetamol</h4> <p>There is insufficient evidence in favor of paracetamol for the acute treatment of migraine in children or adolescents. We only identified one small cross‐over study, predominantly in children, where oral paracetamol was not superior to placebo or ibuprofen. </p> </section> <section id="CD005220-sec-0061"> <h4 class="title">Ibuprofen</h4> <p>Ibuprofen was more effective than placebo in producing pain freedom in two small studies involving children. In one small cross‐over study in adolescents, ibuprofen was not superior to placebo for pain freedom, but it was for headache relief (<a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a>). While ibuprofen as a non‐steroidal anti‐inflammatory drug (NSAID) may have some advantage in the treatment of a migraine attack, considering the presence of neurogenic inflammation (<a href="./references#CD005220-bbs2-0053" title="LevyD , Zhang X-C, JakubowskiM , BursteinR . Sensitization of meningeal nociceptors: inhibition by naproxen. European Journal of Neuroscience2008;27(4):917-22. [DOI: 10.1111/j.1460-9568.2008.06068.x]">Levy 2008</a>), it was not superior to zolmitriptan or paracetamol in two three‐way cross‐over studies (<a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a>; <a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a>). Ibuprofen was not associated with an increase in adverse events overall. </p> </section> <section id="CD005220-sec-0062"> <h4 class="title">Triptans</h4> <p>Triptans as a class of medication were more effective than placebo in producing pain freedom in 3 studies involving children and 21 studies involving adolescents. We did not observe any significant differences in the effect sizes between the subgroups of individual triptans, including almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, or zolmitriptan. While there was some evidence to suggest that intranasal preparations of sumatriptan and zolmitriptan produce higher effect sizes than oral preparations of all the triptans listed above, the evidence was inconsistent. Evidence for the efficacy of the triptans was variable, as measured through the secondary outcomes of headache relief, use of rescue medication, headache recurrence, presence of nausea, and presence of vomiting, but in general it favored the triptans. The efficacy, however, is counterbalanced with an increased risk of minor (non‐serious) adverse events overall. However, there were no serious adverse events reported. Commonly reported adverse events included fatigue, dizziness, asthenia, dry mouth, and nausea or vomiting with oral preparations, and taste disturbance, nasal symptoms, and nausea with intranasal preparations. The combination of sumatriptan with naproxen sodium was also more effective than placebo in producing pain freedom in one adolescent study. We did not observe any significant differences in the effect sizes between studies that included children versus adolescents. The only significant study characteristic that was associated with a higher effect size was the use of a cross‐over design versus parallel group design. </p> </section> <section id="CD005220-sec-0063"> <h4 class="title">Dihydroergotamine</h4> <p>There is insufficient evidence for oral dihydroergotamine in the treatment of migraine in children or adolescents. We only identified one small cross‐over study, which found that oral dihydroergotamine was not superior to placebo. </p> </section> </section> <section id="CD005220-sec-0064"> <h3 class="title" id="CD005220-sec-0064">Overall completeness and applicability of evidence</h3> <p>Of the 27 randomized controlled trials we identified on migraine symptom relieving medications used in the outpatient setting for children and adolescents, 24 belonged to the triptan class, including almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. Pharmaceutical companies sponsored most of the triptan studies (N = 19). We only identified three studies of the most frequently used pain medications (paracetamol and ibuprofen) and none examining other non‐steroidal anti‐inflammatory drugs (NSAIDs) or early treatment (<a href="./references#CD005220-bbs2-0044" title="GoadsbyPJ . The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia2008;28(Suppl 2):36-41. [DOI: 10.1111/j.1468-2982.2008.01689.x]">Goadsby 2008</a>; <a href="./references#CD005220-bbs2-0065" title="SuthisisangCC , PoolsupN , SuksomboonN , LertpipopmethaV , TepwitukgidB . Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache2010;50(5):808-18. [DOI: 10.1111/j.1526-4610.2010.01635.x]">Suthisisang 2010</a>). We only identified one study on a combination medication (sumatriptan plus naproxen sodium). </p> </section> <section id="CD005220-sec-0065"> <h3 class="title" id="CD005220-sec-0065">Quality of the evidence</h3> <p>We judged the quality of evidence for the effect of triptans on pain relief to be moderate, having downgraded it due to serious inconsistency in adolescents and imprecision in children (small sample size, few events, and wide confidence intervals. For ibuprofen, we downgraded the quality of the evidence by two levels to low due to very serious imprecision (small sample size, few events, and wide confidence intervals). It is likely that future research will help to tighten the confidence intervals around the effect size of the above medications. More evidence is needed to assess the effect of paracetamol in children and adolescents. Although we identified heterogeneity between the results in the triptan studies, we believe that further research is unlikely to change the direction of the effect. </p> </section> <section id="CD005220-sec-0066"> <h3 class="title" id="CD005220-sec-0066">Potential biases in the review process</h3> <p>The reviewers searched the indexed and gray literature extensively to identify all published and unpublished studies of medications used in the treatment of migraine in children and adolescents. Pharmaceutical company clinical trial registries were available for sumatriptan, sumatriptan + naproxen sodium, rizatriptan, and zolmitriptan studies, and we identified some negative trials in these sources. The absence of trial registries for the other medications may bias the identification of other negative trials. The funnel plot examination suggested some potential for publication bias, but the Egger statistical tests for bias were not significant. </p> </section> <section id="CD005220-sec-0067"> <h3 class="title" id="CD005220-sec-0067">Agreements and disagreements with other studies or reviews</h3> <p>A number of similar systematic reviews have been published. The review by <a href="./references#CD005220-bbs2-0056" title="MajorPW , GrubisaHSI , ThieNMR . Triptans for treatment of acute pediatric migraine: a systematic literature review. Pediatric Neurology2003;29(5):425-9. [DOI: 10.1016/S0887-8994(03)00400-4]">Major 2003</a> of triptan studies in children and adolescents aged 6 to 18 years concluded that intranasal sumatriptan was effective, while other oral triptans were not. The American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society have published a practice parameter on the pharmacological treatment of migraine (<a href="./references#CD005220-bbs2-0054" title="LewisD , AshwalS , HersheyA , HirtzD , YonkerM , SilbersteinS . Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology2004;63(12):2215-24. [DOI: 10.1212/01.WNL.0000147332.41993.90]">Lewis 2004</a>). Our conclusions are similar with regard to the evidence for efficacy of ibuprofen in children but differ with regard to the efficacy of paracetamol. The practice parameter also concluded that sumatriptan nasal spray was effective for the acute treatment of migraine in adolescents. <a href="./references#CD005220-bbs2-0040" title="DamenL , BruijnJK , VerhagenAP , BergerMY , PasschierJ , KoesBW . Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics2005;116(2):e295-302. [DOI: 10.1542/peds.2004-2742]">Damen 2005</a> evaluated all randomized controlled trials for the acute treatment of migraine in children and adolescents less than 18 years of age but identified a smaller number of trials (10 studies). The authors performed a meta‐analysis, and concluded there was evidence for the use of ibuprofen, paracetamol, and intranasal sumatriptan. <a href="./references#CD005220-bbs2-0061" title="SilverS , GanoD , GerretsenP . Acute treatment of paediatric migraine: a meta-analysis of efficacy. Journal of Paediatrics &amp; Child Health2008;44(1-2):3-9. [DOI: 10.1111/j.1440-1754.2007.01206.x]">Silver 2008</a> also included all medications for the acute treatment of migraine in their search, but identified only 11 studies in children and adolescents under 18 years of age. The authors concluded that there was evidence only for the use of ibuprofen and sumatriptan and did not differentiate between oral and intranasal sumatriptan preparations. A meta‐analysis and qualitative review of ibuprofen and paracetamol in adults, adolescents, and children concluded that ibuprofen was at least as efficacious as paracetamol (<a href="./references#CD005220-bbs2-0057" title="PierceCA , VossB . Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Annals of Pharmacotherapy2010;44(3):489-506. [DOI: 10.1345/aph.1M332]">Pierce 2010</a>). <a href="./references#CD005220-bbs2-0043" title="EilandLS , HuntMO . The use of triptans for pediatric migraines. Paediatric Drugs2010;12(6):379-89. [DOI: 10.2165/11532860-000000000-00000]">Eiland 2010</a> recommended the triptan class as an acute treatment option for children and adolescents with migraines, also concluding that there was evidence to recommend sumatriptan and zolmitriptan nasal sprays as well as rizatriptan or almotriptan tablets over the other triptans. <a href="./references#CD005220-bbs2-0068" title="VollonoC , VigevanoF , TarantinoS , ValerianiM . Triptans other than sumatriptan in child and adolescent migraine: literature review. Expert Review of Neurotherapeutics2011;11(3):395-401. [DOI: 10.1586/ern.10.147]">Vollono 2011</a> examined 11 studies and concluded that triptans are an important option in the symptomatic treatment of childhood and adolescent migraine. Individually, they found that zolmitriptan and rizatriptan were superior to placebo in most studies, and almotriptan was well tolerated. <a href="./references#CD005220-bbs2-0067" title="ToldoI , De CarloD , BolzonellaB , SartoriS , BattistellaPA . The pharmacological treatment of migraine in children and adolescents: an overview. Expert Review of Neurotherapeutics2012;12(9):1133-42. [DOI: 10.1586/ern.12.104]">Toldo 2012</a> recommended paracetamol and ibuprofen as first line treatments for migraine in children and adolescents. The triptans were deemed safe, and the authors concluded that sumatriptan nasal spray was more effective than placebo and that zolmitriptan nasal spray and rizatriptan tablets were likely effective. <a href="./references#CD005220-bbs2-0070" title="Wöber-Bingöl Ç. Pharmacological treatment of acute migraine in adolescents and children. Paediatric Drugs2013;15(3):235-46. [DOI: 10.1007/s40272-013-0019-3]">Wöber‐Bingöl 2013</a> examined 14 studies on triptans in adolescents and 6 studies in children and concluded that evidence for the acute pharmacological treatment of migraine in children was poor, but evidence for adolescents was better, albeit still limited. The authors outlined that sumatriptan nasal spray and zolmitriptan nasal spray were approved for adolescents in Europe; while in the United States almotriptan can be used for adolescents and rizatriptan is approved for patients aged 6 to 17 years. The combination of sumatriptan and naproxen sodium in adolescents has also since been approved for use in adolescents in the United States. <a href="./references#CD005220-bbs2-0038" title="BonfertM , StraubeA , SchroederAS , ReilichP , EbingerF , HeinenF . Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics2013;44(1):3-19. [DOI: 10.1055/s-0032-1330856]">Bonfert 2013</a> included 33 studies examining acute and preventive treatment for migraine and tension‐type headaches. The reviewers did not conduct a meta‐analysis but reviewed the individual studies, concluding that ibuprofen and paracetamol should be considered first and second line therapies for the acute treatment of migraine in children and adolescents, with almotriptan and rizatriptan as suitable third‐line agents. </p> <p>Finally, a recent review identified only seven studies in adolescents aged 12 to 17 years and concluded that enrichment designs significantly reduced placebo response (<a href="./references#CD005220-bbs2-0064" title="SunH , BastingsE , TemeckJ , MenA , TandonV , MurphyD , et al. Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. JAMA Pediatrics2013;167(3):243-9. [DOI: 10.1001/jamapediatrics.2013.872]">Sun 2013</a>). Our review includes a higher number of studies (N = 27), including negative studies published only in pharmaceutical‐industry sponsored trial registries. We draw similar conclusions with regard to the benefit and safety of ibuprofen in treating children and adolescents with migraine. As with previous reviews, the low cost, broad availability, and safety may make ibuprofen a preferred first choice. We differ however in our conclusion that there is insufficient evidence to recommend paracetamol. In general our conclusions are similar with regard to the triptans as a class of medication being effective in the treatment of children and adolescents with migraine. We differ in that we found insufficient evidence to recommend one triptan over the others in our meta‐analysis and sub‐group analyses. While rizatriptan, sumatriptan, and zolmitriptan were statistically superior to placebo as subgroups, the overall test for subgroup heterogeneity was not significant. In our meta‐analysis, we combined the studies of triptan medications irrespective of route of delivery and dosage. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005220-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005220-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005220-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005220-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 7 Triptans vs placebo in Adolescents, outcome: 7.1 Pain‐free." data-id="CD005220-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 7 Triptans vs placebo in Adolescents, outcome: 7.1 Pain‐free.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Ibuprofen vs placebo in Children, outcome: 2.1 Pain‐free." data-id="CD005220-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ibuprofen vs placebo in Children, outcome: 2.1 Pain‐free.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 7 Triptans vs placebo in Adolescents, outcome: 7.1 Pain‐free." data-id="CD005220-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 7 Triptans vs placebo in Adolescents, outcome: 7.1 Pain‐free.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ibuprofen vs placebo in children, Outcome 1: Pain‐free" data-id="CD005220-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Ibuprofen vs placebo in children, Outcome 1: Pain‐free</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ibuprofen vs placebo in children, Outcome 2: Adverse events (any)" data-id="CD005220-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Ibuprofen vs placebo in children, Outcome 2: Adverse events (any)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ibuprofen vs placebo in children, Outcome 3: Headache relief" data-id="CD005220-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Ibuprofen vs placebo in children, Outcome 3: Headache relief</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ibuprofen vs placebo in children, Outcome 4: Rescue medication" data-id="CD005220-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Ibuprofen vs placebo in children, Outcome 4: Rescue medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ibuprofen vs placebo in children, Outcome 5: Headache recurrence" data-id="CD005220-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Ibuprofen vs placebo in children, Outcome 5: Headache recurrence</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Triptans vs placebo in children, Outcome 1: Pain‐free" data-id="CD005220-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Triptans vs placebo in children, Outcome 1: Pain‐free</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Triptans vs placebo in children, Outcome 2: Adverse events (any)" data-id="CD005220-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Triptans vs placebo in children, Outcome 2: Adverse events (any)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Triptans vs placebo in children, Outcome 3: Headache relief" data-id="CD005220-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Triptans vs placebo in children, Outcome 3: Headache relief</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Triptans vs placebo in children, Outcome 4: Rescue medication" data-id="CD005220-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Triptans vs placebo in children, Outcome 4: Rescue medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Triptans vs placebo in children, Outcome 5: Headache recurrence" data-id="CD005220-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Triptans vs placebo in children, Outcome 5: Headache recurrence</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Triptans vs placebo in children, Outcome 6: Presence of nausea" data-id="CD005220-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Triptans vs placebo in children, Outcome 6: Presence of nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Triptans vs placebo in children, Outcome 7: Presence of vomiting" data-id="CD005220-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Triptans vs placebo in children, Outcome 7: Presence of vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Triptans vs placebo in adolescents, Outcome 1: Pain‐free" data-id="CD005220-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Triptans vs placebo in adolescents, Outcome 1: Pain‐free</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Triptans vs placebo in adolescents, Outcome 2: Adverse events (any)" data-id="CD005220-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Triptans vs placebo in adolescents, Outcome 2: Adverse events (any)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Triptans vs placebo in adolescents, Outcome 3: Headache relief" data-id="CD005220-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Triptans vs placebo in adolescents, Outcome 3: Headache relief</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Triptans vs placebo in adolescents, Outcome 4: Rescue medication" data-id="CD005220-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Triptans vs placebo in adolescents, Outcome 4: Rescue medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Triptans vs placebo in adolescents, Outcome 5: Headache recurrence" data-id="CD005220-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Triptans vs placebo in adolescents, Outcome 5: Headache recurrence</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Triptans vs placebo in adolescents, Outcome 6: Presence of nausea" data-id="CD005220-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Triptans vs placebo in adolescents, Outcome 6: Presence of nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Triptans vs placebo in adolescents, Outcome 7: Presence of vomiting" data-id="CD005220-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Triptans vs placebo in adolescents, Outcome 7: Presence of vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Triptans vs placebo in adolescents, subgroup analysis, Outcome 1: Pain‐free by route (oral or intranasal)" data-id="CD005220-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Triptans vs placebo in adolescents, subgroup analysis, Outcome 1: Pain‐free by route (oral or intranasal) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Triptans vs placebo in adolescents, subgroup analysis, Outcome 2: Sumatriptan vs placebo by route (oral or intranasal)" data-id="CD005220-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Triptans vs placebo in adolescents, subgroup analysis, Outcome 2: Sumatriptan vs placebo by route (oral or intranasal) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Triptans vs placebo in adolescents, subgroup analysis, Outcome 3: Zolmitriptan vs placebo by route (oral or intranasal)" data-id="CD005220-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Triptans vs placebo in adolescents, subgroup analysis, Outcome 3: Zolmitriptan vs placebo by route (oral or intranasal) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Triptans vs placebo in adolescents, subgroup analysis, Outcome 4: Pain‐free by preventive medication" data-id="CD005220-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Triptans vs placebo in adolescents, subgroup analysis, Outcome 4: Pain‐free by preventive medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Triptans vs placebo by age, subgroup analysis, Outcome 1: Age group" data-id="CD005220-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Triptans vs placebo by age, subgroup analysis, Outcome 1: Age group</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 1: Study design" data-id="CD005220-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 1: Study design </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 2: Allocation concealment" data-id="CD005220-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 2: Allocation concealment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 3: Source of funding" data-id="CD005220-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 3: Source of funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 4: Reported in a journal" data-id="CD005220-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 4: Reported in a journal </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005220-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/urn:x-wiley:14651858:media:CD005220:CD005220-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 5: Sample size" data-id="CD005220-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_t/tCD005220-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Triptans vs placebo in adolescents, sensitivity analysis, Outcome 5: Sample size </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/media/CDSR/CD005220/image_n/nCD005220-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005220-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Should ibuprofen be used to treat children with migraine?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Ibuprofen compared with placebo in children with migraine</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : acute treatment of migraine in children<br/><b>Setting</b> : ambulatory<br/><b>Intervention</b> : ibuprofen<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with Ibuprofen</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain freedom at 2 h</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.87<br/>(1.15 to 3.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⨁⨁◯◯<sup>b,c</sup><br/>Low </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>499 per 1000<br/>(307 to 811) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> <p>(− 13 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RD 0.00</p> <p>(− 0.13 to 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality</b> : We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality</b>: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>RD</b>: risk difference </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The response in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>b</sup>In the two studies, there were no serious risks of bias, inconsistency, indirectness, or publication bias. We downgraded quality of evidence by two levels due to very serious imprecision (small sample size, few events, and wide confidence interval). </p> <p><sup>c</sup>High (⨁⨁⨁⨁) = further research is very unlikely to change our confidence in the estimate of effect; Moderate (⨁⨁⨁◯) = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low (⨁⨁◯◯) = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very Low (⨁◯◯◯) = any estimate of effect is very uncertain. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Should ibuprofen be used to treat children with migraine?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005220-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Should triptans be used to treat children with migraine?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Triptans compared with placebo in children with migraine</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : acute treatment of migraine in children<br/><b>Setting</b> : ambulatory<br/><b>Intervention</b> : triptans<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with triptans</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain freedom at 2 h</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.67<br/>(1.06 to 2.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>345<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⨁⨁⨁◯<sup>b,c</sup><br/>MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Includes rizatriptan oral (1 study) and sumatriptan by nasal spray (2 studies)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>461 per 1000<br/>(292 to 723) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>176 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000</p> <p>(− 7 to 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RD 0.06</p> <p>(− 0.04 to 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>420</p> <p>(3 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality</b> : We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality</b>: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>RD</b>: risk difference. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The response in the intervention group (and its 95% confidence interval) is based on the assumed response in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>b</sup>In the three studies, there were no serious risks of bias, inconsistency, indirectness, or publication bias detected. Quality of evidence was downgraded by one level due to serious imprecision (small sample size, few events, and wide confidence interval). </p> <p><sup>c</sup>High (⨁⨁⨁⨁) = further research is very unlikely to change our confidence in the estimate of effect; Moderate (⨁⨁⨁◯) = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low (⨁⨁◯◯) = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very Low (⨁◯◯◯) = any estimate of effect is very uncertain. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Should triptans be used to treat children with migraine?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005220-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Should triptans be used to treat adolescents with migraine?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Triptans compared with placebo in adolescents with migraine</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : acute treatment of migraine in adolescents<br/><b>Setting</b> : ambulatory<br/><b>Intervention</b> : Triptans<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with Triptans</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain freedom at 2 h</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(1.19 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6761<br/>(21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⨁⨁⨁◯<sup>b,c</sup><br/>MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Includes almotriptan (1 study), eletriptan (1 study), naratriptan (1 study), rizatriptan (4 studies), sumatriptan (10 studies), and zolmitriptan (4 studies) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>303 per 1000<br/>(273 to 338) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>184 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>24 per 1000</p> <p>(15 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RD 0.13</p> <p>(0.08 to 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7876</p> <p>(21 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality</b> : We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality</b>: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>RD</b>: risk difference. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The response in the intervention group (and its 95% confidence interval) is based on the assumed response in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>b</sup>Serious inconsistency was observed in the effect estimates. All of the triptans with only 1 study were not statistically superior to placebo (i.e. almotriptan, eletriptan, naratriptan) in producing pain freedom while the three triptans with 2 or more studies (i.e. rizatriptan, sumatriptan, and zolmitriptan) were statistically significant with a higher magnitude of effect. In the subgroup analysis of the individual triptan groups through, the subgroup differences were not statistically significant (P = 0.45). </p> <p><sup>c</sup>High (⨁⨁⨁⨁) = further research is very unlikely to change our confidence in the estimate of effect; Moderate (⨁⨁⨁◯) = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low (⨁⨁◯◯) = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very Low (⨁◯◯◯) = any estimate of effect is very uncertain. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Should triptans be used to treat adolescents with migraine?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005220-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Should sumatriptan plus naproxen sodium be used to treat adolescents with migraine?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Sumatriptan + naproxen sodium compared with placebo in adolescents with migraine</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : acute treatment of migraine in adolescents<br/><b>Setting</b> : ambulatory<br/><b>Intervention</b> : sumatriptan + naproxen sodium<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Response with Sumatriptan + naproxen sodium</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain freedom at 2 h</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.66<br/>(1.57 to 4.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>485<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⨁⨁⨁◯<sup>b,c</sup><br/>MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Doses including sumatriptan + naproxen 10 mg + 60 mg, 30 mg + 180 mg, and 85 mg + 500 mg were all well tolerated and demonstrated similar efficacy </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<br/>(163 to 394) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 per 1000</p> <p>(− 2 to 7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RD 0.03</p> <p>(− 0.02 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>490</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality</b> : We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality</b> : We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality</b> : Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality</b>: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>RD</b>: risk difference. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The response in the intervention group (and its 95% confidence interval) is based on the assumed response in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><sup>b</sup>The confidence interval of the effect size is wide. The true effect may be substantially different than the estimated effect in producing pain freedom. </p> <p><sup>c</sup>High (⨁⨁⨁⨁) = further research is very unlikely to change our confidence in the estimate of effect; Moderate (⨁⨁⨁◯) = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low (⨁⨁◯◯) = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very Low (⨁◯◯◯) = any estimate of effect is very uncertain. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Should sumatriptan plus naproxen sodium be used to treat adolescents with migraine?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005220-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>N <b>= 27<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study design</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Sponsorship</b> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharmaceutical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐pharmaceutical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Age inclusion criteria</b> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adolescents (12‐17 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children (&lt; 12 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Pain scale</b> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐faces scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Preventive medication permitted?</b> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Route of delivery</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intranasal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Medications</b> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibuprofen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triptans</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>Triptan medications</b> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Almotriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eletriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naratriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rizatriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan + naproxen sodium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolmitriptan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>DHE</b> : dihydroergotamine; <b>VAS</b>: visual analogue scale. </p> <p><sup>a</sup>The total number of studies listed in Medications does not add up to 27 as two studies (<a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a> &amp; <a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a>) compared multiple medications. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005220-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary table of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review Manager ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Child.</b> </p> <p><b>(&lt; 12 yrs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adolesc.</b> </p> <p><b>(12‐17 yrs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>% Female</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Paracetamol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Ibuprofen</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0007" title="HämäläinenML , HoppuK , ValkeilaE , SantavuoriP . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology1997;48(1):103-7. [DOI: 10.1212/WNL.48.1.103]">Hämäläinen 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0012" title="LewisDW , KellsteinD , DahlG , BurkeB , FrankLM , ToorS , et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache2002;42(8):780-6. [DOI: 10.1046/j.1526-4610.2002.02180.x]">Lewis 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Triptans (&lt; 12 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0011" title="HoTW , PearlmanE , LewisD , HämäläinenM , ConnorK , MichelsonD , et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Headache2012;32(10):750-65. [DOI: 10.1177/0333102412451358]">Ho 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0021" title="UeberallMA , WenzelD . Intranasal sumatriptan for the acute treatment of migraine in children. Neurology1999;52(7):1507-10. [PMID: 10227648]">Ueberall 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0010" title="HämäläinenM , JonesM , LoftusJ , SaiersJ . Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. International Journal of Clinical Practice2002;56(9):704-9. [PMID: 12469987]SUM30009. A single centre, placebo-controlled, double blind, randomised cross-over, single attack study evaluating the efficacy and tolerability of sumatriptan nasal spray 10 mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura. http://www.gsk-clinicalstudyregister.com/study/SUM30009#rs (accessed 24 June 2015). ">Hämäläinen 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Triptans (12‐17 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0014" title="LinderSL , MathewNT , CadyRK , FinlaysonG , IshkanianG , LewisDW . Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache2008;48(9):1326-36. [DOI: 10.1111/j.1526-4610.2008.01138.x]">Linder 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>60%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0027" title="PitmanV . Efficacy, safety and tolerability of oral eletriptan (40 mg) for the treatment of migraine in adolescents (12-17 years). Headache2000;40(5):424-5. WinnerP , LinerSL , LiptonRB , AlmasM , ParsonsB , PitmanV . Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache2007;47(4):511-8. [DOI: 10.1111/j.1526-4610.2007.00755.x]">Winner 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0016" title="RothnerA , EdwardsK , KerrL , DeBusseyS , AsgharnejadM . Efficacy and safety of naratriptan tablets in adolescent migraine. Journal of Neurological Sciences1997;150(Suppl 1):S106. S2WA3012. A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population. http://www.gsk-clinicalstudyregister.com/study/S2WA3012#rs (accessed 24 June 2015). ">Rothner 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0011" title="HoTW , PearlmanE , LewisD , HämäläinenM , ConnorK , MichelsonD , et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Headache2012;32(10):750-65. [DOI: 10.1177/0333102412451358]">Ho 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>61%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0022" title="VisserWH , WinnerP , StrohmaierK , KlipfelM , PengY , McCarrollK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache2004;44:891-9. [DOI: 10.1111/j.1526-4610.2004.04171.x]">Visser 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>55%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0025" title="WinnerP , LewisD , VisserWH , JiangK , AhrensS , EvansJK , et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache2002;42(1):49-55. [DOI: 10.1046/j.1526-4610.2002.02013.x]">Winner 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0002" title="AhonenK , HämäläinenML , EerolaM , HoppuK . A randomized trial of rizatriptan in migraine attacks in children. Neurology2006;67(7):1135-40. [DOI: 10.1212/01.wnl.0000238179.79888.44]">Ahonen 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>54%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0003" title="CallenbachPM , PelsLP , MulderPG , LinssenWH , GooskensRH , Van der ZwanJL , et al. Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children. European Journal of Paediatric Neurology2007;11(6):325-30. [DOI: 10.1016/j.ejpn.2007.02.010]SUM30042. A multi-centre, randomised, double-blind, placebo-controlled, cross-over study to investigate the efficacy, safety and tolerability of sumatriptan nasal spray (10mg or 20mg) in the treatment of migraine in patients aged 12-17. http://www.gsk-clinicalstudyregister.com/study/SUM30042#rs (accessed 24 June 2015). ">Callenbach 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>78%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0018" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. ">Rothner 1999b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>52%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0024" title="WinnerP , RothnerAD , SaperJ , NettR , AsgharnejadM , LaurenzaA , et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics2000;106(5):989-97. [PMID: 11061765]">Winner 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>52%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0008" title="HämäläinenML , HoppuK , SantavuoriP . Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?Neurology1997;48(4):1100-3. [PMID: 9109909]">Hämäläinen 1997b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>52%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0019" title="RotherD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. [GSK ID: S2CT40]">Rothner 1999c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>42%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0006" title="FujitaM , SatoK , NishiokaH , SakaiF . Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia2014;34(5):365-75. [DOI: 10.1177/0333102413510213]SUM111035. A randomized, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral sumatriptan for the acute treatment of migraine in children and adolescents. http://www.gsk-clinicalstudyregister.com/study/111035#ps (accessed 24 June 2015). ">Fujita 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>58%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0023" title="WinnerP , PrenskyA , LinderS , DeBusseyS , AsgharnejadM . Adolescent migraine: efficacy and safety of sumatriptan tablets. Journal of the Neurological Sciences1997;150(Suppl 1):S172. [DOI: 10.1016/S0022-510X(97)85694-8]">Winner 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>58%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0026" title="SUM30045. A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (5mg And 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 years of age). http://www.gsk-clinicalstudyregister.com/study/SUM30045#rs (accessed 24 June 2015). WinnerP , RothnerAD , WootenJD , WebsterC , AmesM . Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache2006;46(2):212-22. [DOI: 10.1111/j.1526-4610.2006.00339.x]WinnerP , RothnerD , WebsterCJ , AmesMH , KoriSH . Randomized, double-blind, placebo- controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology2004;62(7 Suppl 5):A182. ">Winner 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>55%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0001" title="AhonenK , HämäläinenML , RantalaH , HoppuK . Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology2004;62(6):883-7. [DOI: 10.1212/01.WNL.0000115105.05966.A7]">Ahonen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>46%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0017" title="RothnerD , AsgharnejadM . Tolerability of sumatriptan tablets in the acute treatment of migraine in adolescent patients: a review of data from clinical trials. European Journal of Neurology1999;6(Suppl 3):106. SUMB2003. A double-blind, randomised, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg) in the acute treatment of migraine in adolescents. http://www.gsk-clinicalstudyregister.com/study/SUMB2003#rs (accessed 24 June 2015). ">Rothner 1999a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0004" title="DerosierFJ , LewisD , HersheyAD , WinnerPK , PearlmanE , RothnerAD , et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics2012;129(6):e1411-20. [DOI: 10.1542/peds.2011-2455]">Derosier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Sumatriptan and</p> <p>Naproxen Sodium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0013" title="LewisDW , WinnerP , HersheyAD , WaslewskiWW , Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics2007;120(2):390-6. [DOI: 10.1542/peds.2007-0085]">Lewis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0005" title="EversS , RahmannA , KraemerC , KurlemannG , DebusO , HusstedtIW , et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology2006;67(3):497-9. [DOI: 10.1212/01.wnl.0000231138.18629.d5]">Evers 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0020" title="RothnerAD , WasiewskiW , WinnerP , LewisD , StankowskiJ . Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache2006;46(1):101-9. [DOI: 10.1111/j.1526-4610.2006.00313.x]">Rothner 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005220-bbs2-0015" title="NCT01211145. Zomig - treatment of acute migraine headache in adolescents (TEENZ). clinicaltrials.gov/ct2/show/NCT01211145 (accessed 24 June 2015). ">NCT01211145</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Dihydroergotamine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD005220-bbs2-0009" title="HämäläinenM , HoppuK , SantavuoriPR . Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatric Neurology1997;16(2):114-7. [DOI: 10.1016/S0887-8994(96)00289-5]">Hämäläinen 1997c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>PO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>38%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>IN: intranasal; NA: not applicable; ND: no data available; No: total number in efficacy analysis (intention‐to‐treat when available); PO: per os (by mouth). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary table of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/full#CD005220-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005220-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ibuprofen vs placebo in children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Pain‐free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.15, 3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Adverse events (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.13, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Headache relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.11, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Headache recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.01, 5.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ibuprofen vs placebo in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005220-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Triptans vs placebo in children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Pain‐free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.06, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.89, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.00, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Adverse events (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.04, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.09, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Headache relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.88, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.75, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.21, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.06, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.06, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Headache recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Presence of nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.46, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.38, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.42, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Presence of vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.13, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.43, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.09, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Triptans vs placebo in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005220-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Triptans vs placebo in adolescents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Pain‐free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.19, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.88, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.88, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.65, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.13, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.10, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.6 Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.16, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Adverse events (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.08, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.05, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.02, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.09, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.6 Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.07, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Headache relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.04, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.10, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.65, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.99, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.5 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.02, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.6 Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.87, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.72, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.28, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.59, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.55, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.4 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.55, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.5 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.70, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.6 Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.20, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Headache recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.44, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.53, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.42, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.4 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.30, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.5 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.65, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.6 Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.36, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Presence of nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.04, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.66, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.4 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.49, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.5 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.78, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.6 Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.04, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Presence of vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.48, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Almotriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Eletriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Naratriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.24, 16.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.4 Rizatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.22, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.5 Sumatriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.39, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.6 Zolmitriptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.79, 1.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Triptans vs placebo in adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005220-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Triptans vs placebo in adolescents, subgroup analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Pain‐free by route (oral or intranasal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.19, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.08, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Intranasal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.32, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Sumatriptan vs placebo by route (oral or intranasal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.10, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Intranasal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.15, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.75, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Zolmitriptan vs placebo by route (oral or intranasal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.16, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Intranasal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.46, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.42, 9.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Pain‐free by preventive medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.19, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Preventive medication not permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.14, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Preventive medication permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.04, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Unsure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.11, 1.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Triptans vs placebo in adolescents, subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005220-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Triptans vs placebo by age, subgroup analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Age group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.06, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Mixed children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.96, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 Adolescent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.18, 1.45]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Triptans vs placebo by age, subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005220-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Triptans vs placebo in adolescents, sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.19, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Cross‐over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.44, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Parallel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.12, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.19, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.12, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Source of funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Pharmaceutical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.16, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 Non‐pharmaceutical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [1.50, 11.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.22, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Reported in a journal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Journal report</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.18, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 Registry or abstract only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.94, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Sample size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.19, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Sample size ≤ 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [1.50, 11.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.2 Sample size &gt; 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.18, 1.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Triptans vs placebo in adolescents, sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005220.pub2/references#CD005220-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005220.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD005220-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD005220-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005220-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005220-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005220-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD005220-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD005220-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD005220-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005220-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005220-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005220\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005220\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005220\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005220\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005220\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005220.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005220.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005220.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005220.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005220.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727593056"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005220.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727593060"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005220.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eafd93e45936d',t:'MTc0MDcyNzU5My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 